South Dakota State University

Open PRAIRIE: Open Public Research Access Institutional
Repository and Information Exchange
Electronic Theses and Dissertations
2021

Exploration of Host Health Benefits by a Defined Consortium of
Butyrate-Producing Human Gut Bacteria In Gnotobiotic Mouse
Model
Linto Antony
South Dakota State University

Follow this and additional works at: https://openprairie.sdstate.edu/etd
Part of the Microbiology Commons

Recommended Citation
Antony, Linto, "Exploration of Host Health Benefits by a Defined Consortium of Butyrate-Producing Human
Gut Bacteria In Gnotobiotic Mouse Model" (2021). Electronic Theses and Dissertations. 5277.
https://openprairie.sdstate.edu/etd/5277

This Thesis - Open Access is brought to you for free and open access by Open PRAIRIE: Open Public Research
Access Institutional Repository and Information Exchange. It has been accepted for inclusion in Electronic Theses
and Dissertations by an authorized administrator of Open PRAIRIE: Open Public Research Access Institutional
Repository and Information Exchange. For more information, please contact michael.biondo@sdstate.edu.

EXPLORATION OF HOST HEALTH BENEFITS BY A DEFINED CONSORTIUM
OF BUTYRATE-PRODUCING HUMAN GUT BACTERIA IN GNOTOBIOTIC
MOUSE MODEL

BY
LINTO ANTONY

A dissertation submitted in partial fulfillment of the requirements for the
Doctor of Philosophy
Major in Biological Sciences
Specializing in Veterinary Microbiology
South Dakota State University
2021

ii
DISSERTATION ACCEPTANCE PAGE
Linto Antony

This dissertation is approved as a creditable and independent investigation by a candidate
for the Doctor of Philosophy degree and is acceptable for meeting the dissertation
requirements for this degree. Acceptance of this does not imply that the conclusions
reached by the candidate are necessarily the conclusions of the major department.

JOY SCARIA
Advisor

Date

Jane Hennings
Department Head

Date

Nicole Lounsbery, PhD
Director, Graduate School

Date

iii

“This dissertation is dedicated to Almighty God and my loving family”

iv
ACKNOWLEDGEMENTS
I would like to thank all those who helped and supported me in completing my Ph.D.
research work. I would like to thank Dr. Joy Scaria for the opportunity he gave me to do
my dissertation research in his lab and for the guidance he provided along the way. My
sincere gratitude to all my advisory committee members Dr. Radhey Kaushik, Dr. Eric
Nelson and Dr. Kunsoon Park for their valuable support. I express my gratitude to all
current and previous lab colleagues for their help, critiques, and support. A special thanks
to Julie for the immense help she provided for my research work and dissertation writing.
Most importantly a huge thanks to my wife Maria, our son Johannes and all other
members of my family for their relentless support. Finally, a great thanks to Almighty
God for His grace in me.

v
CONTENTS
ABBREVIATIONS .................................................................................................x
LIST OF FIGURES ............................................................................................. xiv
LIST OF TABLES .............................................................................................. xvii
ABSTRACT....................................................................................................... xviii
1

2

LITERATURE REVIEW .................................................................................1
1.1

Introduction ...............................................................................................1

1.2

Bacterial therapeutics from gut microbiota ...............................................2

1.3

Microbial fermentation and SCFA production..........................................4

1.4

Transportation/mechanism of SCFA .........................................................8

1.5

Importance of Short chain Fatty Acids (SCFA) ........................................9

1.6

Butyrate function/ beneficial role of butyrate in host health ...................10

1.6.1

Immunological functions .................................................................10

1.6.2

Physiological functions ....................................................................12

1.7

Butyrate producers in the gut microbiota ................................................13

1.8

Relevance of having butyrate producers in gut microbiota.....................13

1.9

Butyrate producers as bacterial therapeutics ...........................................14

1.10

Conclusion...............................................................................................16

CHAPTER 1. selection of potential members for a bacterial therpaeutic consortium

from human gut bacteria collection .......................................................................18
2.1

Introduction .............................................................................................18

vi
2.2

Materials and methods ............................................................................19

2.2.1

Bacteria culture and maintenance ....................................................19

2.2.2

Prediction of terminal genes (but and buk) of butyrate production pathways
..........................................................................................................20

2.2.3

In-vitro testing of butyrate production .............................................20

2.2.4

Gas chromatography (GC) analysis for SCFA ................................21

2.2.5

Animal experiments .........................................................................21

2.2.6

Genomic DNA extraction ................................................................22

2.2.7

16S rRNA gene amplicon sequencing .............................................23

2.2.8

16S rRNA sequencing based bacterial community profiling. .........24

2.2.9

Strain abundance mapping ...............................................................24

2.3

Results and discussion.............................................................................25

2.3.1

Genotypic screening of selected bacteria for the biomarkers of butyrate

production .......................................................................................................25
2.3.2

Phenotypic confirmation of the butyrate production in in-vitro cultures
…………………………………......................................................27

2.3.3

Abundance of selected bacterial strains in the individual and pooled donor

sample ..........................................................................................................30
2.3.4

Colonization fitness of the selected bacteria in the mouse gut when

introduced as complex microbiota..................................................................31
2.3.5

Effect of diet, disease, and antibiotics on the colonization stability 35

vii
2.4
3

Conclusion...............................................................................................38

CHAPTER 2. Assessment of colonization and host health benefits by a defined

consortium of four butyrate producing human gut bacteria in gnotobiotic mouse model
........................................................................................................................39
3.1

Introduction .............................................................................................39

3.2

Materials and methods ............................................................................42

3.2.1

Bacterial culture and maintenance ...................................................42

3.2.2

Gnotobiotic mice experiment ...........................................................42

3.2.3

Total RNA extraction from tissue ....................................................44

3.2.4

Gel electrophoresis...........................................................................45

3.2.5

cDNA preparation ............................................................................46

3.2.6

Quantitative RT-PCR based Gene expression profile using RT2 profiler

PCR-arrays .....................................................................................................47
3.2.7

Lymphocytes separation from mouse PBMC ..................................51

3.2.8

Lymphocytes separation from mouse spleen ...................................51

3.2.9

Flowcytomtery .................................................................................52

3.3

Results and Discussion ............................................................................57

3.3.1

Colonization and community formation in germ free mice .............57

3.3.2

Butyrate and other SCFA production potential of emerged community
..........................................................................................................61

viii
3.3.3

Effect on the gut health by the colonization of BPC assessed by

histopathology ................................................................................................62
3.3.4

Modulation of the host immunology and physiology by the colonization of

BPC

..........................................................................................................64

3.4
4

Conclusion...............................................................................................77

CHAPTER 3. Protective effect of butyrate producing consortium against DSS

induced colitis ........................................................................................................78
4.1

Introduction .............................................................................................78

4.2

Material and Methods..............................................................................79

4.2.1

Bacterial strain abundance mapping ................................................79

4.2.2

Mice experiment ..............................................................................79

4.2.3

DSS induction of colitis in mice ......................................................80

4.2.4

Fecal occult blood test .....................................................................81

4.2.5

Colon tissue gene expression profiling using qRT-PCR .................81

4.3

Results and Discussion ............................................................................83

4.3.1

Association of selected butyrate producers in healthy and IBD conditions
..........................................................................................................83

4.3.2

Prophylactic role of BPC against DSS induced colitis ....................86

4.3.2.1

Microbial community structure and composition before and after the

induction of colitis ................................................................................................ 86

ix
4.3.2.2

Health assessment of the colon when induced colitis after colonized

with BPC. ............................................................................................................. 88

4.4

4.3.2.3

Gene expression profile of colon tissue ............................................... 90

4.3.2.4

Modulation of immune cell profile by BPC in colitis condition ......... 96

4.3.2.1

DSS effect on SCFA profile ................................................................ 99

Conclusion.............................................................................................101

5

Summary.......................................................................................................102

6

Literature Cited .............................................................................................104

x
ABBREVIATIONS
AD: Alzheimer's disease
AP-1: Activator protein-1
AMP: Antimicrobial peptide
BHI: Brain heart infusion
BLAST: Basic local alignment search tool
BLASTn: Nucleotide BLAST
BPC: Butyrate producing consortium
Buk: butyrate kinase
But: butyryl-CoA:acetate CoA-transferase
CD: Crohn’s disease
CDI: Clostridium difficile infection
cDNA: Complimentary deoxyribonucleic acid
cfu: colony forming unit
CLA: Conjugated linoleic acid
CO2: Carbon dioxide
CH4: Methane
CT: Cycle Threshold
DEPC: Diethyl pyrocarbonate
DMSO: Dimethyl sulfoxide
DNA: Deoxyribose nucleic acid
DPBS: Dulbecco’s PBS
DPI: Day post inoculation
DSS: Dextran sulfate sodium
DTT: Dithiothreitol

xi
EA: Ethyl acetate
EC: Enterochromaffin cells
EECs: Enteroendocrine cells
FABP: fatty acid binding protein
FFA: Free fatty acid
FMT: Fecal microbiota transplantation
Gapdh: Glyceraldehyde phosphate dehydrogenase
GC: Gas chromatography
GF: Germ free
GIT: Gastrointestinal tract
GLP-1: Glucagon like peptide -1
GMO: Genetically modified organisms
GPRs: G-protein-coupled receptors
HDAC: histone deacetylase
hFMT: Human fecal microbiota transplant
5-HT: 5-hydroxytryptamine
H2: Hydrogen
IACUC: Institutional animal care and use committee
IBD: Inflammatory bowel disease
IBS: Irritable bowel syndrome
ICD: Ileal crohn’s disease
IgA: Immunoglobulin A
Insl5: Insulin-like peptide 5
IL-10: Interleukin 10
LBPs: Live biotherapeutic products

xii
MET: Microbiota ecosystem therapeutics
MCT: Monocarboxylate transporter
MGWAS: Metagenome-wide association study
MNC: mononuclear cells
mTOR: Mammalian target of rapamycin
uL: microliter
uM: micromolar
NCBI: National center for biotechnology information
NFW: Nuclease free water
ng: Nanogram
NGPs: Next-generation probiotics
OD: Optical density
PCR: Polymerase chain reaction
PBMC: Peripheral blood mononuclear cells
PBS: Phosphate buffered saline
PUFA: Poly unsaturated fatty acid
PYG: Peptone Yeast extract glucose
QIIME: Quantitative insights into microbial ecology
qRT-PCR: Quantitative real time PCR
RBC: Red blood cells
rCDI: recurrent Clostridium difficile Infection
RELMβ / Retnlb: Resistin-like molecule β
Reg3g: Regenerating islet-derived protein 3 gamma
Reg3b: Regenerating islet-derived protein 3 beta
RNA: Ribonucleic Acid

xiii
rRNA: Ribosomal RNA
ROS: Reactive oxygen Species
RPM: Rotation per minute
SCFA: Short chain fatty acids
SDSU: South Dakota State University
STAT3: Signal transducers and activator of transcription 3
TAE: Tris base, acetic acid and EDTA
TGF- β: Transforming growth factor-β
TJP: Tight junction proteins
T1D: Type 1 diabetets
T2D: Type 2 diabetes
UC: Ulcerative colitis
UV: Ultra-violet
WGS: Whole genome sequencing
ZO-1: Zona occludens

xiv
LIST OF FIGURES
Figure 1. Propionate production pathways in human gut bacteria...................................... 6
Figure 2. Butyrate synthesis pathways identified in human gut bacteria.. ......................... 8
Figure 3. Multiple effects produced by butyrate in the gut............................................... 10
Figure 4. Taxonomy details of the four butyrate producing bacteria selected for this study
........................................................................................................................................... 28
Figure 5. Abundance of selected bacterial strains in the donor stool samples. ................ 31
Figure 6. Stable colonization of selected butyrate producers in the mouse gut. ............... 37
Figure 7. Experimental concept. ....................................................................................... 43
Figure 8. Experimental outline. ........................................................................................ 44
Figure 9. Cell staining panels used for immune cell profiling using flow cytometry. ..... 53
Figure 10. Gating strategy used for profiling different populations of lymphocytes under
panel 1 ............................................................................................................................... 55
Figure 11. Gating strategy used for profiling different populations of lymphocytes under
panel 2 ............................................................................................................................... 56
Figure 12. Total bacterial load in the feces of gnotobiotic mouse.. .................................. 58
Figure 13. Total viable bacterial load enumerated from the cecal contents. .................... 59
Figure 14. Relative abundance of the BPC members in the cecal content of gnotobiotic
mice. ................................................................................................................................ 60
Figure 15. SCFA profile in the cecal content of gnotobiotic mice in comparison to germ
free counterpart.. ............................................................................................................... 61
Figure 16. Histomorphological comparison of colon tissue. ............................................ 63
Figure 17. Gene expression profile of 88 genes in the colon tissue. ................................ 65

xv
Figure 18. Genes that are up or down-regulated more than two-fold change in the
gnotobiotic mice................................................................................................................ 66
Figure 19. Effect of colonization of selected members of human gut bacteria on the
immune cell population of secondary lymphoid organ (Spleen) of the mice. .................. 75
Figure 20. Effect of colonization of selected members of human gut bacteria on the
immune cell population of peripheral blood of the mice. ................................................. 76
Figure 21. Experiment outline for DSS induced colitis experiment ................................. 80
Figure 22. Abundance of BPC members in the IBD and non-IBD gut metagenomic
datasets from Lloyd et al study .. ...................................................................................... 85
Figure 23. Community structure formed by the BPC members before and after DSS
treatment. .......................................................................................................................... 87
Figure 24. Survival plot showing the survival rate of different groups of mice with and
without DSS treatment. ..................................................................................................... 88
Figure 25. Representative figure showing the gross difference in the colon between GF
and BPC treated mice under colitis. .................................................................................. 89
Figure 26. Histopathological comparison of colon tissue after induction of colitis with
DSS. .................................................................................................................................. 90
Figure 27. Expression profile of various inflammatory genes in the colon tissue analyzed
by qRT-PCR...................................................................................................................... 94
Figure 28. Profile of immune cell populations in spleen under colitis condition. ............ 97
Figure 29. Profile of immune cell populations in PBMC under colitis condition. ........... 98
Figure 30. SCFA profile of cecal contents from GF and gnotobiotic mice with colitis. .. 99

xvi
Figure 31. Butyrate level in the cecal content of BPC colonized mice with and without
DSS induced colitis.. ....................................................................................................... 101

xvii
LIST OF TABLES
Table 1.Media conditions used for phenotypic verification of butyrate production......... 21
Table 2. Prediction of terminal genes of bacterial butyrate production pathway.. ........... 27
Table 3. Amount of butyrate detected in cultures of selected bacteria.. ........................... 28
Table 4. The list of components used in the preparation of cDNA .................................. 46
Table 5. Thermal cycler conditions used for RT-PCR ..................................................... 47
Table 6. List of genes screened for their expression in the colon to assess the effect of
bacterial colonization on the host. .................................................................................... 48
Table 7. List of antibodies with flourochrome used for staining the immune cells under
panel 1. .............................................................................................................................. 53
Table 8. List of antibodies with fluorochrome used for staining immune cells under panel
2......................................................................................................................................... 54
Table 9. Details of the mouse qRT-PCR primers used in this study. ............................... 82

xviii
ABSTRACT
EXPLORATION OF HOST HEALTH BENEFITS BY A DEFINED CONSORTIUM
OF BUTYRATE-PRODUCING HUMAN GUT BACTERIA IN GNOTOBIOTIC
MOUSE MODEL
LINTO ANTONY
2021
Aberrant gut microbiota composition is found to be associated with several
human diseases such as inflammatory bowel diseases (IBD). Reduction in butyrate
producing bacteria is one of the characteristic features of such dysbiotic bacterial
community in the gut. Modulation of gut microbiota to bring the dysbiotic state back to
normal healthy state is a promising therapeutic strategy to cure several diseases like
recurrent Clostridium difficile infection (rCDI) and IBD where traditional therapies using
pharmacological substances fails to make a difference. Restoration of butyrate producers
is found to be an effective method of such gut microbiota modulation. The potential to
produce butyrate is phylogenetically diverse and not even present in all members of the
same family. Hence the number of identified bacteria that can produce butyrate is not
vast and most of them were not explored for their functional roles towards host health
benefits. Low abundance and the difficulty to culture these strictly anaerobic organisms
are the few reasons of their under exploration. Here we examine the immunomodulatory
properties of four butyrate producing human gut bacterial species as a defined mix using
gnotobiotic mouse as a model. Our study shows, these allochthonous bacterial strains
assemble in the germ-free mouse gut and produce butyrate as one of the short chain fatty
acids. Without causing any pathological changes, successful colonization of these

xix
bacteria fortifies the innate immune defense system by enhancing the expression of
regenerating islet-derived protein 3 beta (Reg3b), regenerating islet-derived protein 3
gamma (Reg3g), mucin 2 (Muc2) and defensin beta (Defb) genes in the colon and
modulating the adaptive immune cell populations at the systemic levels. However, precolonization of these bacteria did not show any significant changes in pro and antiinflammatory responses in gnotobiotic mice compared to germ free mice under colitis
induced by Dextran sulfate sodium (DSS). But a better gross and histopathological
appearance of colon in gnotobiotic mice indicates that these bacteria have some role in
attenuating colitis rather aggravating it and thus can be considered as candidates of
bacterial therapeutics.
.
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1

LITERATURE REVIEW

………………………………………………………………………….
1.1

Introduction
The human gut microbiota is considered as an “indispensable organ” that

influences a host’s immunological, physiological, and metabolic functions[1-4]. There
are different opinions about using the term “organ”, but it is a co-evolved partner of the
host that affects not only the function of the intestine but also other organs, including the
brain [5, 6]. The diversity of the human gut microbiota in an individual is highly unique
and no two gut microbiomes are identical. However, the functionality of the gut
microbiota remains stable with in a healthy population [7, 8]. The members of the
phylum Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria form the major
proportion of the bacterial community in a healthy adult gut [9], but the composition of
human gut bacteria is highly dynamic and fluctuates during the lifetime of an individual
[10].
Although there is no clear definition for a healthy gut microbiota, an alteration of
the gut microbial community associated with changes in the normal gut physiology and
characterized by lower microbial diversity is broadly described as gut dysbiosis [8, 11,
12]. Disease conditions and medical interventions like antibiotic treatment are few of the
factors that influence the structure of the gut microbiota and results in dysbiosis [11].
This aberrant homeostatic condition has been reported to be associated with several
human diseases. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and
obesity are few of such disease conditions. Although the causal role of dysbiosis in the
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development of majority of these diseases has not yet been proven, bringing the aberrant
microbiota composition back to a homeostatic condition has been found to be effective
in alleviating or attenuating some of those diseases [8].
Since the best therapeutic approach to alter the gut microbiota is not defined,
multiple therapeutic strategies ranging from complex community level interventions (Ex:
Fecal microbiota transplantation (FMT)) to highly targeted (Defined bacterial mix)
approaches are being explored by researchers [13]. Because of the promising results of
FMT, especially in treating recurrent Clostridium difficile infection (CDI) [14], it has
been widely studied for its therapeutic effects by means of potential microbiome altering
properties. Because of the limitations of FMT, i.e. unknown donor microbial
composition, possibility of having infectious agents in the donor microbiota, and the need
for a qualified donor, other approaches such as the use of a defined bacterial consortium
have been investigated and may have similar therapeutic effects. The benefits of using a
defined consortium approach encourages scientists to explore the gut microbiota to
identify host health promoting microbes and to find a consortium that is therapeutically
effective.
1.2

Bacterial therapeutics from gut microbiota
The advent of high throughput next generation sequencing, as well as advanced

culturing techniques, help us to understand the composition and function of human gut
microbiota. This in turn allowed us to identify gut microbial members that have potential
health benefits for the hosts. These host health supporting organisms are referred to as
next-generation probiotics (NGPs), or live biotherapeutic products (LBPs) [15]. Currently
these beneficial microbes are selected as NGPs based on two scenarios. One scenario is
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the presence of the proposed bacterial strain with healthy status or its absence in a
diseased status and its ability to bring back the healthy phenotype when administered as a
therapeutic agent. The second scenario is the ability of the strain to act as a delivery
vehicle for a bioactive molecule which has some health promoting effect [15]. For
example, Faecalibacterium prausnitzii is considered as a NGP candidate based on the
first scenario as it was reported to be depleted in the Crohn’s disease (CD) patients and its
introduction resulted in the amelioration of colitis conditions in animal models[16, 17].
Genetically modified organisms (GMO) that deliver bioactive molecules to the host
belong to NGPs considered under the second scenario. Genetically engineered
Lactococcus lactis has been used to deliver interleukin 10 (IL-10) for preventing allergic
sensitization caused by food allergens [18] while transforming growth factor-β (TGF-β)
producing engineered Bacteroides ovatus has been found to be effective in treating colitis
condition [19].
Primarily, a microbial consortium designed for therapeutic purposes consists of
natural strains of bacteria selected by community profiling of the microbiota from healthy
and diseased patients [20]. One of the major functional attributes of potential candidates
for therapeutic use would be the ability of the bacteria to ferment complex carbohydrates
and the production short chain fatty acids (SCFA). Commensal bacteria that can produce
SCFA satisfy the criteria of NGP selection because depletion of SCFA producing
bacteria, especially butyrate producers, has been reported to be associated with several
disease conditions [21-23]. These bacteria are the original sources of biologically active
metabolites, SCFA, which play role in the immune homeostasis of the host and disease
prevention. For example, because of the various functions of butyric acid elicited in the

4
host, it has been considered as a potential therapeutic agent for use against IBD. A
decrease of butyrate producers in the gut of IBD patients suggests the use of butyrate
producers as next generation probiotics [24]. Studies showing attenuation of
inflammation and necrosis in rodent IBD models when treated with butyrate producers
from cluster IV and XIVa are evidence for the use of butyrate producers as
biotherapeutics [16, 24, 25].
1.3

Microbial fermentation and SCFA production
The carbohydrates in our diet can be of two types, simple and complex

carbohydrates. Simple carbohydrates, like simple sugars and starch, are easily digested in
the small intestine while complex carbohydrates are resistant to enzymatic digestion in
the upper gastrointestinal (GI) tract. Cellulose, hemicellulose, arabinoxylans,
arabinogalactans, inulin, and pectins are a few examples of such complex carbohydrates
otherwise known as dietary fibers [26, 27]. Many of these complex carbohydrates, after
varying degrees of breakdown, reach the large intestine or colon and undergo microbial
fermentation [28]. A dense population of bacteria, up to 1012 viable bacteria per gram
colon content, colonized in the human large intestine is responsible for this microbial
fermentation [29]. The major products of the fermentative reaction in the adult human
colon is SCFA together with gases like CO2, CH4 and H2. More than 95% of the
bacterially derived SCFA are absorbed while in transit through the colon and that process
represents the major flow of carbon from diet to host. A comparable rate of colonic
uptake has been reported for major SCFA [28]. Host, environment, diet and
microbiological factors are the major regulators of bacterial synthesis of SCFA. The
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amount and the type of SCFA produced in a healthy gut depends on the substrate
availability, gut bacterial composition and the intestinal transit time [30].
Acetate, propionate and butyrate are the major SCFA produced by the microbial
fermentation in the gut. The pathways responsible for the production of acetate are
widely distributed while that for propionate and butyrate are highly conserved [31]. There
are three known pathways of propionate production in human gut bacteria - succinate
pathway, acrylate pathway, and propanediol pathway. Using genomic and metagenomic
approaches, the distribution of these three pathways in the gut microbiota has been
explored by Reichardt et al [32] (Figure 1). Members of the phylum Bacteroidetes and
Firmicutes utilize the succinate pathway for propionate synthesis. Since Bacteroidetes
forms the most abundant portion of human gut microbiota, the succinate pathway was the
most common mechanism for propionate synthesis. The acrylate pathway showed a
limited distribution and only in members of the Firmicutes. The propanediol pathway
had a wide distribution and most bacteria having the gene repertoire for this pathway
belonged to Lachnospiraceae members [32].
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Figure 1. Propionate production pathways in human gut bacteria. Succinate pathway (P1),
acrylate pathway (P2), and propanediol pathway (P3) are the three major pathways of
propionate synthesis identified in the human gut bacteria. Adapted from Reichardt et al,
2014 [32].

Similarly, for butyrate synthesis, Vital et al [33] performed a study using genomic
and metagenomic analysis to find out the distribution of various pathways of butyrate
synthesis in human gut bacteria and to identify potential butyrate producers. The AcetylCoA, glutarate, 4-aminobutyrate, and lysine pathways are the four known pathways for
bacterial butyrate synthesis where amino acids serve as major substrates for the last three
pathways [33-36] (Figure 2). These four pathways merge to a central step where
crotonyl-CoA is converted to butyryl-CoA. As a final step, butyryl-CoA is transformed to
butyrate by either butyryl-CoA:acetate CoA transferase or butyrate kinase that are
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encoded by but and buk respectively. These two genes (but and buk) were used as
biomarker genes for identifying butyrate producing bacteria [37, 38].
Analysis based on genome screening for key genes of butyrate synthesis pathways
by Vital et al identified the presence of butyrate synthesis pathways in the genomes of
225 organisms. They found the acetyl-CoA pathway as the most abundant pathway,
followed by the lysine pathway. The glutarate and 4-aminobutyrate pathways were the
least abundant ones [33]. A similar trend of pathway abundance was noticed in the
analysis of 15 stool samples coming from healthy individuals. Members of the phylum
Firmicutes formed the major butyrate producing bacterial group with Acetyl CoA
pathway as the dominant one while other pathways were least represented. In contrast,
the phylum Bacteroidetes exhibited three pathways of butyrate synthesis [33].
Some of the interesting findings from the above studies regarding the SCFA
pathways in the gut bacteria may be worth noting here. One study by Vital et al [33]
shows that genes of two or three butyrate pathways were found to be present in several
isolates, indicating butyrate synthesis as critical step in their metabolic pathways.
However, butyrate synthesis pathways were not consistently present in all the members
of the same family. Pathways using amino acids as their substrate were often found with
the acetyl-CoA pathway and not alone. One of the interesting findings of the study by
Reichardt et al is that, except in very few human gut bacteria, the biomarker genes for
butyrate synthesis were absent in most of the isolates with genes for propionate
production and vice versa [32].
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Figure 2. Butyrate synthesis pathways identified in human gut bacteria. Figure adapted
from Vital et al, 2014 [33] shows four butyrate synthesis pathways know to present in
human gut microbiota and associated genes.
1.4

Transportation/mechanism of SCFA
SCFA are weak acids that are present in GIT as anionic state rather than free acid

form and require transporters for absorption [39]. Similar mechanisms consisting of
several transport systems exists in both the small and large intestine for the absorption of
SCFA, but the transporters for SCFA are expressed at different levels in these two
regions of intestine [39, 40]. Monocarboxylate transporter (MCT)1 (SLC16A1), sodiumcoupled MCT(SMCT)2 (SLC5A12) and SLC16A7 are seen in small intestine while
MCT1 (SLC16A1), SMCT2 (SLC5A12), SMCT1 (SL5CA8) and SLC26A3 are found in
colon [40]. Affinity of these transporters differ, for example some of them show affinity
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for all three major SCFA. Transporters MCT1, SMCT1 and SLC26A3 belong to that
category. Some others are selective in their affinity, for example SMCT2 transports only
butyrate [40].
In humans, SCFA are sensed by six G-protein -coupled receptors (GPRs) - GPR41
(FFAR3), GPR42, GPR43 (FFAR2), GPR109a (HCAR2), GPR164 (OR51E1) and
OR51E2- that are expressed by various cell types. These receptors differ in their affinity
towards SCFA. All three major SCFA are recognized by GPR43 (FFAR2) and GPR41
(FFAR3), while only butyrate is recognized by GPR109a (HCAR2) [39, 41, 42]. GPR42
is expressed in colon and activated by propionate, whereas GPR164 senses butyrate and
is expressed all along the GIT. Propionate and acetate act as ligands for OR51E2 in
humans. Activation of these G-protein-coupled receptors by their respective ligands
trigger downstream cell signaling mechanisms.
1.5

Importance of Short chain Fatty Acids (SCFA)
SCFA are the end products of saccharolytic fermentation of undigested

carbohydrates by the gut microbiota. Acetate, propionate and butyrate are the main SCFA
produced by this microbial fermentation in the colon where the amount of SCFA depends
on the composition of microbiota and the diet. Since the SCFA are readily absorbed from
the colon, determination of the physiological level is hard, however the amount of the
main SCFA are found to be in the molar ratio of 60:20:20. Around 15% of the total
energy uptake of humans is accounted by the amount of SCFA produced in the gut [29].
More than being fuel for gut epithelial cells, SCFA also have roles in the epithelial cell
proliferation, differentiation, apoptosis, gut barrier integrity, gut motility, host
metabolism and host immune modulation.

10
1.6

Butyrate function/ beneficial role of butyrate in host health
Butyrate has been studied extensively for its role in host health. A broad picture of

the major functions of butyrate in the colon has been shown in the Figure 3. It acts as the
preferred energy substrate for colonocytes [39]. At the same time, it plays a critical role
in the colonic defense system of the host.

Figure 3. Multiple effects produced by butyrate in the gut. (Adapted from Guilloteau et
al, 2010).

1.6.1

Immunological functions
The intestinal epithelial barrier is one of the host defense mechanisms that help

prevent bacterial translocation and the associated inflammatory responses. Being the
important regulator of tight junction proteins (TJP), butyrate plays an immense role in the
maintenance of the integrity of this barrier. It enhances the expression of tight junction
component proteins claudin-1, and zona occludens (ZO-1) or reverses their decreased
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expression and causes redistribution of these proteins thus allowing better barrier
functions [43, 44].

Enhancement of barrier function by butyrate is not limited to TJP assembly. Also,
butyrate modulates the mucus layer protecting the mucosa as well as the antimicrobial
peptide (AMP) production by the intestinal epithelium. The influence of butyrate on
mucus layer thickness has been verified by both in vitro and in vivo studies. A fourfold
increase in the in vitro mucin synthesis by colonic biopsy specimens has been reported by
Finnie et al when treated with sodium butyrate [45]. Treatment of a human polarized
colonic goblet cell line with butyrate as the energy source enhanced the expression of
various MUC genes including MUC2, a prominent mucin secreted by intestinal epithelial
cells [46].
As a response to gut microbiota, host intestinal epithelial cells produce
antimicrobial peptides (AMPs) that are important components needed for maintaining
intestinal homeostasis. Defensins, cathelicidins and C-type lectins are different families
of AMPs, the production of some of these are regulated by the microbiota. For example,
Zhao et al [47] showed that butyrate enhances the expression of RegIIIγ and β defensins
via the activation of GPR43 receptors and the induction of downstream signaling of
mammalian target of rapamycin (mTOR) and signal transducers and activator of
transcription 3 (STAT3) pathways. By this mechanism, butyrate helps to increase the
defense against both Gram-negative and Gram-positive organisms.
It was not only through epithelial cells that butyrate enhanced the antimicrobial
activity and the host defense system, but also through other cells like macrophages. By
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shifting the macrophage metabolism through histone deacetylase 3 (HDAC3) inhibition,
butyrate caused increased antimicrobial activity by the macrophages that was even
evident in in vivo experiments and caused increased resistance to enteric pathogens [48].
Treatment of LPS stimulated dendritic cells with butyrate caused increased expression of
IL-23 and the T cells stimulated by these DCs produced increased IL-17 and IL-10 [49].
While in another study, they show that butyrate treatment of LPS induced DCs cause
polarization of naïve CD4+ T cells to IL-10 producing regulatory T cells [50]. However,
both these responses happened because of the histone deacetylase (HDAC) inhibition
activity of butyrate and the same activity also caused differentiation of naïve T cells into
regulatory T cells in the gut [51, 52].

1.6.2

Physiological functions
Butyrate was found to be a potent activator of the activator protein-1 (AP-1)

signaling pathway that has important roles in cell proliferation, apoptosis and intestinal
epithelial cell differentiation, the balance of which are critical in case of human colorectal
cancer [53]. Butyrate is not known for its potent anti-oxidant activity, however it can
stimulate antioxidant enzymes or compounds that can reduce the damage caused by
reactive oxygen species (ROS) [54] and it was reported to reduce oxidative stress and
thereby reduce DNA damage caused by hydrogen peroxide [55].
SCFA in general are involved in the regulation of enteric hormones produced by
the gut enteroendocrine cells (EECs). L cells in the gut mucosal lining secrete glucagonlike peptide 1 (GLP-1) and peptide YY (PYY) that are involved in the regulation of
satiety and appetite. Results from both in vivo and in vitro studies have shown that
butyrate influences the expression of GLP-1 and PYY and thus produces its effect on
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satiety [56-59]. Enterochromaffin (EC) cells are known to produce serotonin (5hydroxytryptamine, 5-HT) which is a neurotransmitter involved with gastric motility and
secretion. SCFA, including butyrate, can act as stimuli that promote the enteric
production and homeostasis of 5-HT [60].

1.7

Butyrate producers in the gut microbiota
Although most of the butyrate producing bacteria are under the Order Clostridiales

in the phylum Firmicutes, metagenomic analysis shows that potential butyrate producers
are also distributed in other phyla such as Actinobacteria, Bacteroidetes, Fusobacteria,
Proteobacteria, Spirochaetes, and Thermotogae[33]. In the phylum Firmcutes, most of the
butyrate producers belong to families Clostridiaceae, Eubacteriaceae, Lachnospiraceae,
and Ruminococcaceae, in Clostridial clusters IV, XIVa, XVI, and I [33, 61, 62]. For
example, extensively studied butyrate-producing bacteria Faecalibacterium prausnitzii
belonged to cluster IV and Roseburia spp., Anerostipes spp., Clostridium spp.,
Ruminococcus spp and Eubacterium rectale are in cluster XIVa [62]. By analyzing for
butyrate synthesis pathways and associated genes in the bacterial genomes, Vital et al
identified 225 bacterial strains having the potential for butyrate synthesis. The potential
of butyrate production was not present in all the members of the same family [33].
1.8

Relevance of having butyrate producers in gut microbiota
Butyrate-producing members of the gut microbiota carry out important functions to

help maintain homeostasis in the gut. Alteration of the gut microbiota characterized by
reduced butyrate producers in certain disease manifestations further confirm the necessity
of butyrate producers in the gut microbial community for healthy status of the host. One
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example of disease conditions manifested because of altered microbiota occurs in IBD
patients found to have decreased numbers of butyrate producer F. prausnitzii from
Clostridium cluster IV as compared to healthy individuals [63-66]. F. prausnitzii, having
anti-inflammatory properties as well as producing butyrate, is lower in patients with CD
and IBS [16, 67].
Altered gut microbiota is considered a risk factor even in metabolic diseases. A
metagenome-wide association study (MGWAS) of Type 2 diabetes (T2D) patients and
non-diabetic controls showed a decline of butyrate producing species such as
Clostridiales sp. SS3/4, Eubacterium rectale, Faecalibacterium prausnitzii, Roseburia
intestinalis and Roseburia inulinivorans in T2D stool samples while they were found
enriched in control group [68]. Moreover, enrichment of SCFA producing strains
including butyrate producers by therapeutic intervention with dietary fiber and the
resultant clinical improvements in T2D shows the need of butyrate producers to maintain
glucose homeostasis and diabetes prevention [69]. An inverse association of butyrate
producing bacteria was found in the gut microbiota composition of children with β -cell
autoimmunity and susceptibility to Type 1 diabetes (T1D) [21].
1.9

Butyrate producers as bacterial therapeutics
Administration of pure butyrate compounds in the form of tablets or enemas has

been tried as therapeutic interventions against IBD to make use of the beneficial
properties of butyrate [70]. Failure to properly deliver butyrate to gut, short exposure of
the gut to butyrate, and poor patient compliance were several confounding factors that
caused problems in these trials [24, 71]. The absorption of butyrate in the small intestine
is one of the major reasons for an improper dosage to reach to colon by the oral
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administration of butyrate [72]. Use of prebiotics such as a high fiber diet as a source of
endogenous production of butyrate was another option and found useful in T2D as it
caused enrichment of butyrate producers in the gut microbial community [69]. However,
the success of such treatments depends on the presence of butyrate producing bacteria
and the type of fiber supplement.
Synbiotics, food ingredients or dietary supplements combining probiotics and
prebiotics, which produce butyrate as an end product of their cross feeding may be
therapeutic and be an improved treatment strategy in comparison to introducing
individual butyrate producers to the gut [73]. Unfortunately, we cannot assure the
success of such combination as the nature of cross feeding may change when the
community is introduced into gut preoccupied by several other organisms.
For sustained release of butyrate, introducing a combination of different butyrate
producing bacteria as probiotics, or live biotherapeutics, to restore butyrate producers
would be another approach. Since the majority of butyrate-producing bacteria are strictly
anaerobic organisms, isolation and culturing was difficult previously. However,
improvised and high through put anaerobic culturing techniques now available allowed
us to overcome this struggle. Transient or sustained enrichment or colonization of those
bacteria can result in increased production of butyrate and greater therapeutic effect. A
colonizing bacterium that can act as microbial effector of anti-inflammatory as well as
immunoregulatory processes, along with increased butyrate production would be
considered an ideal probiotic [24]. In vitro treatment with butyrate producing bacteria
alone or in combination to IBD microbiota resulted in enrichment of butyrate producers
in the altered IBD microbiota as well as enhancing the SCFA profile. Successful
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colonization in IBD microbiota and increased butyrate production was achieved when
treated with multi species of six butyrate-producing bacteria [74]. Introduction of
butyrate producers as a treatment strategy has been successful in in vivo studies as well.
Treatment with F. prausnitzi resulted in counterbalancing the aberrant microbiota
community in mouse IBD model [16]. In another study, treatment with Butyricicoccus
pullicaecorum resulted in attenuation of colitis in rat IBD model. T. prausnitzi and
Butyricicoccus pullicaecorum are butyrate-producing bacteria belonging to Clostridial
cluster IV. Thus, further exploration of butyrate producers from cluster IV and XIVa may
identify potential candidates for next generation probiotics [24].
1.10 Conclusion
Understanding of the bacterial members of the human gut microbiota opens a new
era in microbiology where researchers find beneficial bacterial members from the coevolved microbial community. Next generation sequencing and advanced culturomic
techniques allow us to mine new strains that have potential probiotic or therapeutic
properties from the human gut. Unlike traditional probiotic approaches, identification
and use of gut-derived strains in their natural state may be a better approach for
therapeutic interventions. Identification of microbial effector strains that can colonize
when introduced, contribute to maintenance of host immune homeostasis directly or
indirectly via metabolites, and restore eubiosis has become the focus of the scientific field
of microbial therapeutics. Considering the myriads of health promoting effects produced
by butyrate, finding strains that have the potential to produce this natural microbial
metabolite along with other beneficial properties is one of the promising strategies to
formulate next generation probiotics or therapeutics. Finding such effective candidates
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and generating a successful therapeutically efficient consortium is a long-term goal based
on ceaseless efforts and every attempt of scientific community towards this focus is a
milestone in therapeutic microbiology.
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CHAPTER 1. SELECTION OF POTENTIAL MEMBERS FOR A BACTERIAL
THERPAEUTIC CONSORTIUM FROM HUMAN GUT BACTERIA
COLLECTION
2.1

Introduction

……………………………………………………………………………
Restoration of a healthy balance of intestinal microbiota via fecal microbiota
transplantation (FMT) is a promising treatment strategy for diseases related with gut
dysbiosis [75, 76]. Its remarkable effectiveness and incredible success in the treatment of
recurrent Clostridium difficile infection (CDI) with a cure rate of 90% [77] expanded its
use to other gut dysbiosis associated diseases like IBD [78, 79]. However, there are
several regulatory issues exists with regards to safety and efficacy of this treatment
methodology [80]. Although it may be safe, it has been reported to be associated with
short term and long-term adverse events like diarrhea, vomiting, flatulence, obesity,
diabetes, colon cancer, nonalcoholic fatty liver disease etc. Varying patient responses in
different studies associated with route and interval of FMT administration and variation
in the composition and bacterial load in the donor stool samples are few draw backs of
this treatment method. Lack of comprehensive guidelines for donor selection, stool
preparation, dosage regimen, recipient preparation and long-term safety are other
limitations associated with FMT [80, 81]. This demands further improvisations and
standardizations with more controlled clinical trials and research to establish FMT as a
standalone treatment strategy [78, 81].
An alternative approach avoiding the associated concerns of FMT would be the
use of synthetic stool substitute or otherwise called microbiota ecosystem therapeutics
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(MET). The basis of this treatment strategy is the use of a mix of pre-defined bacteria
isolated from stool of a healthy donor. Effectiveness of such multi-species community of
bacteria to cure recurrent CDI has already been demonstrated [82]. A standardized stoolderived microbial ecosystem therapeutic (MET-1) comprising 33 bacterial strains from
the fecal sample of a healthy individual successfully cured recurrent CDI in two patients
[82, 83]. Rebalance of dysbiotic gut microbial ecosystem with well-defined bacterial
species thus proposed as an improved alternative treatment strategy to total FMT [81].
There are not many known commensals that can be used as potential bacterial
therapeutics. Identification of 11 strains from a healthy human donor feces that can
enhance pathogen resistance and ani cancer immunity in host [84], and isolation of 17
bacterial strains, from human indigenous microbiota, that can enhance Treg cell
abundance and induce anti-inflammatory action [85] are few of successful efforts towards
that objective. Focusing on the defined bacterial therapeutics, this study aims to identify
commensal bacteria based on their potential to produce butyrate, a bacterial metabolite
that has anti-inflammatory and immunomodulatory function.

2.2 Materials and methods
……………………………………………………………………
2.2.1

Bacteria culture and maintenance
Until otherwise mentioned, all bacteria were cultured in anaerobic brain heart

infusion (BHI) medium with L-cysteine as reducing agent and resazurin as oxygen
indicator. Cultures were maintained at 37oC inside anaerobic chamber (Coy Laboratory
Products Inc.) with 85% nitrogen, 10% carbon dioxide and 5% hydrogen.
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2.2.2

Prediction of terminal genes (but and buk) of butyrate production pathways
Final genes in the bacterial butyrate synthesis pathway, butyryl-CoA:acetate CoA-

transferase(but) and butyrate kinase (buk) genes, were used as biomarkers for the
identification of butyrate producing community [33, 38]. We checked the presence of
these two genes in a set of 10 bacterial strains, preselected from the human gut bacterial
culture collection prepared in our lab [86], using local BLASTn search in CLC Genomics
workbench. v12.0 (Qiagen). Using nucleotide sequences of genes but and buk from
National center for biotechnology information (NCBI), a custom database was generated,
and the genomes were queried against this custom database using resistance finding
method in CLC Genomics workbench. v12.0. A minimum query coverage of 50% and a
sequence identity of 30% was used for the BLAST search.
2.2.3

In-vitro testing of butyrate production
Six bacteria that were predicted for the presence of but and buk genes were further

tested for their ability to produce butyrate in in-vitro culture conditions. Overnight
cultures of selected bacteria were inoculated in to three different media conditions in
anaerobic chamber (Coy Laboratory Products Inc.) ( Table 1). Two of them were BHI
broth and yeast extract-based media with and without inulin as a complex carbohydrate
supplement. For the third media condition, DSMZ’s modified peptone yeast extract
glucose (PYG) medium was used. After 24 hours of incubation, 100uL of the culture was
mixed with 500uL of 5% freshly prepared meta-phosphoric acid. The mixture was
vortexed thoroughly for two minutes and immediately stored at -80oC until further
processing for gas chromatography (GC).
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Table 1.Media conditions used for phenotypic verification of butyrate production. Table
shows three media conditions used for checking in-vitro butyrate production by the
selected bacteria.
MI
MII
MIII

2.2.4

BHI broth supplemented with inulin
BHI broth
DSMZ’s modified Peptone Yeast extract Glucose

Gas chromatography (GC) analysis for SCFA
Immediately before GC analysis, samples were thawed and vortexed for 2

minutes. Ethyl acetate (EA) extraction method described by Garcia-Villalba et al [87],
was used for the detection of SCFA. In brief, homogenized sample was then centrifuged
for 10 min at 17,949 × g. Each milliliter of supernatant was then extracted with 1 mL of
organic solvent ie, EA for 2 min and centrifuged for 10 min at 17,949 × g. A minimum of
200 uL volume of the organic phase per sample was used to load in the Trace 1300 gas
chromatogram (Themo fisher scientific).
2.2.5

Animal experiments
Germ free (GF) mice (C57BL/6) purchased from Taconic Biosciences. Inc. were

used for colonization study. Both male and female mice of six weeks of age were orally
gavaged with pooled fecal sample prepared in our previous work [86]. Human fecal
microbiota transplanted mice (hFMT mice) were then maintained under ad libitum
normal chow diet and drinking water. After several generations of breeding, fecal
samples were collected from four to six weeks old mice to check the presence of four
butyrate producing bacteria selected for this study. To check the colonization stability of
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those four bacteria in the mice gut when exposed to diet change, disease condition and
antibiotic treatment, four to six weeks old hFMT mice were grouped in to three groups.
One group of mice received 1% inulin in the drinking water for 3 days as a diet change.
Another group was treated with 2.5% Dextran Sulfate Sodium (DSS) in drinking water
for 5 days to induce colitis as a disease condition. Third group was treated with a cocktail
of antibiotics [kanamycin (0.4 mg per mL), gentamicin (0.035 mg per mL), colistin (850
U per mL), metronidazole (0.215 mg per mL), and vancomycin (0.045 mg per mL)] for 5
days in drinking water. Fecal samples were collected after treatment for genomic DNA
extraction and bacterial community profiling. All animal experiments were performed
with the prior approval of the protocols by South Dakota State University (SDSU) animal
studies committee and under the regulations of Institutional Animal Care and Use
Committee (IACUC), SDSU policies.
2.2.6

Genomic DNA extraction
Genomic DNA from the fecal samples were extracted using DNeasy power soil

kit (Qiagen) according to the manufacturer’s instructions. Briefly, around 200 to 250mg
per samples were subjected to bead beating along the chemical lysis to ensure proper
homogenization and lysis of microbial cells. Lysis was then followed by precipitation and
separation of non-DNA organic and inorganic substances including protein to improve
the DNA quality. This was then followed by treatment with highly concentrated salt
solution and then transferring to silica membrane. At high salt concentration, DNA will
bind to the silica membrane which in turn facilitated further cleaning by ethanol
containing wash solution. After cleaning, DNA attached to the silica membrane was
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eluted using nuclease free water. Quality of the extracted DNA was then assessed using
NanoDrop (Thermo Scientific).
2.2.7

16S rRNA gene amplicon sequencing

The 16s rRNA gene sequencing was performed according to Illumina protocol
where PCR amplificons targeting the V3-V4 region of the bacterial 16s rRNA gene was
used for sequencing. Bacterial primer pairs -16S Amplicon PCR Forward Primer = 5’
CCTACGGGNGGCWGCAG, and 16S Amplicon PCR Reverse Primer = 5'
GACTACHVGGGTATCTAATCC (Illumina, Inc.) were used for the amplification of
region of interest. These locus-specific primers were attached with overhang adaptors,
Forward overhang: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG, and
Reverse overhang: 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG at the 5’
end of the respective primer sequences. A 25 µl reaction was set up for each sample using
a template microbial DNA concentration of 5ng/ µl (2.5 µl), primers at concentration 1
µM (5µl each) and 2x KAPA HiFi Hot Start Ready-mix (12.5 µl). Polymerase chain
reaction (PCR) was performed using the following cycle conditions: 95°C for 3 minutes,
25 cycles of: 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds, followed
by 72°C for 5 minutes and hold at 4°C. The resulted amplicons (~550bp) thus generated
were then purified from free primers and primer dimer species using AMPure XP beads
(Beckman Coulter). Using the purified amplicons as the template sequencing libraries
were prepared using Nextera XT library preparation kit (Illumina, Inc.). A dual barcoding
system was used for indexing the libraries as per manufacturer’s protocol. Libraries were
then pooled to a single loading library after manually normalizing the concentration of
individual libraries to 4nM. Sequencing was performed on Illumina Miseq platform
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using 2x300 bp paired end read chemistry. Demultiplexed and adaptor trimmed reads
generated by Illumina analytical tools were then used for further processing.
2.2.8

16S rRNA sequencing based bacterial community profiling.

Microbiota profiling from 16S sequencing was performed using Quantitative
Insights Into Microbial Ecology 2 (qiime2) microbiome bioinformatics platform [88]. A
quality control of demultiplexed, adaptor trimmed raw reads were performed using
DADA2 in qiime2 pipeline where primer sequences and low-quality regions (<15) of
both forward and reverse reads were removed prior to merging reads and identifying nonchimeric reads. Taxonomic assignment of representative sequence of each feature was
performed by sklearn feature classifier in qiime2 using a custom database at a minimum
confidence level of 0.70. Use of custom database will improve the sensitivity of the
technique to detect even the low abundant reads of the desired bacteria as 16S rRNA
gene sequencing will not provide identification at strain level as shotgun metagenomics
do. The top hit 16S rRNA gene sequences, when the sanger sequences of four selected
bacteria were BLAST searched against rRNA database in NCBI, were used to generate
the custom database. Before using for taxonomic assignment, reference reads were
extracted from this database and trained the Naive Bayes classifier using these reference
sequences.
2.2.9

Strain abundance mapping
Whole genome sequencing (WGS) data of selected four bacterial strains and

shotgun metagenomic sequencing data of the donor samples from the previous study [86]
were used for the abundance mapping using Kaiju [89]. Briefly a custom database created
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from annotated protein files, that contain amino acid sequences, of four selected bacteria
were used for abundance mapping. Host reads from the metagenomic data were removed
using metaWRAP [90] and then cleaned metagenomic reads were used for abundance
mapping using Kaiju.
2.3 Results and discussion
………………………………………………………………..
Human gut microbiota consists of several species of butyrate producing bacteria,
most of which are less explored for their potential role in the host health as butyrate
producers. To understand the properties of such butyrate-producing bacteria, we
preselected 10 bacterial species that are presumably butyrate producers from the human
gut bacterial culture collection in our lab [86] . Confirmation of genotypic and phenotypic
potential of these bacterial strains to produce butyrate was performed and a final set of
four bacteria, that are less mined for their properties as butyrate producers, were selected.
To explore that these bacteria can be used as key stone species of bacterial therapeutics
such as FMT and defined microbial consortium therapy, colonization fitness and stability
of these four bacteria were then taken as further criteria for their selection. These
properties were then assessed in the context of FMT to germ free mice. Furthermore, this
will also tell us whether mice will be a good model to study the host-microbiome
interaction of these selected bacteria.
2.3.1

Genotypic screening of selected bacteria for the biomarkers of butyrate
production
Bacterial butyrate production involves four main pathways (Acetyl-coenzyme A

(CoA), Lysine, Succinate and Glutarate pathways) which merge to a central energy
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generating step where crotonyl CoA is transformed to butyryl-CoA. Metagenomic
analysis of human fecal samples revealed that Acetyl-CoA pathway is the most prevalent
pathway of butyrate production in the gut microbiota [33]. Major enzymes involved in
the final conversion of butyryl-CoA to butyrate in this pathway are butyryl-CoA:acetate
CoA transferase (encoded by but) or butyrate kinase (encoded by buk) [33, 38]. These
two terminal genes in the butyrate synthesis pathway were used as biomarkers for the
identification of butyrate producers in the microbial community [37, 38, 62].
Thus, in this study, to identify potential butyrate producers, a general approach of
BLAST search for the nucleotide sequences of but and buk genes in the genomes of
selected bacteria was used. A custom database, of available nucleotide sequences of but
and buk downloaded from NCBI, was generated for the same purpose. This genome
screening for the biomarkers of butyrate production resulted in a reduction in the total
number of pre-selected bacterial species from ten to six. Four of the bacterial genomes
did not show any hit with the provided minimum query coverage and sequence identity
(Table 2). All the remaining six bacterial species showed a hit with a minimum sequence
identity of >60%. Except one, all six of them showed a query coverage of >80%. One
species, Megasphaera indica SG-518, showed hits at query cut off 50%. It was mainly
the members of the phylum Firmicutes showed the presence of but and buk in their
genomes. Other than Firmicutes it was Butyricimonas paravirosa SG-1991, a bacterium
from phylum Bacteroidetes showed the presence of biomarkers of butyrate production.
Thus, those six bacteria were selected for further phenotypic analysis.
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Table 2. Prediction of terminal genes of bacterial butyrate production pathway. Table
showing the BLAST search result hit for buk and but genes in the genomes of preselected
set of ten bacterial species.
Bacteria
Butyricimonas paravirosa SG-1991
Agathobacter rectalis SG-1778
Olsenella umbonata SG-635
Coprococcus catus SG-963
Coprococcus comes SG-584
Flavonifractor plautii SG-1616
Catenibacterium mitsuokai SG-899
Megasphaera indica SG-518
Blautia luti SG-1740
Agathobaculum butyriciproducens SG-940

2.3.2

Buk (B1)
YES (>70%ID,80%seql)
NO
NO
NO
YES (>66%ID,80%seql)
NO
NO
NO
NO
NO

But (B2)
NO
YES (>67%ID,80%seql)
NO
YES (>67%ID,80%seql)
NO
NO
NO
YES(>64%ID,50%seql)
NO
YES (>68%ID,80%seql)

Phenotypic confirmation of the butyrate production in in-vitro cultures
To ascertain that bacterial species predicted to be having terminal genes of

butyrate production pathways in their genome are able to produce butyrate, a phenotypic
evaluation of butyrate production in in vitro culture conditions was performed. Three
nutrient rich media under anaerobic conditions were used for this phenotypic validation
of butyrate production. Bacteria that showed detection of butyrate in any one of the
media conditions were selected for further studies. Out of six bacteria tested only four of
them showed detection of butyrate at millimolar concentration in at least one of the three
media conditions tested ( Table 3). Although we predicted butyrate production pathway
genes in the genomes of strains- Agathobacter rectalis SG-1778 and Coprococcus catus
SG-963, we did not get any identifiable peaks in the gas chromatogram of these bacterial
cultures at millimolar concentrations. Hence, these bacteria were removed from the
further studies.
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Table 3. Amount of butyrate detected in cultures of selected bacteria. Table shows the
amount of butyrate produced by selected bacteria in three different media conditions.
(MI: BHI broth supplemented with inulin, MII: BHI broth with no supplements, MIII:
DSMZ’s modified Peptone Yeast extract Glucose)
Taxonomy
Phylum

Family

Bacteroidetes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

Odoribacteraceae
Lachnospiraceae
Lachnospiraceae
Lachnospiraceae
Veillonellaceae
Ruminococcaceae

Bacteria

Butyricimonas paravirosa SG-1991
Agathobacter rectalis SG-1778
Coprococcus catus SG-963
Coprococcus comes SG-584
Megasphaera indica SG-518
Agathobaculum butyriciproducens SG-940

Butyrate (mM)
MII
MIII
0 1.738
0
0
0
0
0
0
4.627
0 2.496
1.574
7.105
2.154
7.373
4.225
10.672

MI
1.468

Thus, a total of four bacteria were selected based on the genotypic and phenotypic
screening for butyrate production (Figure 4). Out of four, three of them were belong to
the phylum Firmicutes and one belongs to the phylum Bacteroidetes that is these four
bacteria represented the two major phyla of the human gut bacteria. Besides, they
represented four different bacterial families and the Gram-positive and Gram-negative
fractions of the human gut bacterial community.

Figure 4. Taxonomy details of the four butyrate producing bacteria selected for this study

Butyricimonas paravirosa is a Gram-negative rod shaped, non-motile, non-spore
forming obligate anaerobic bacteria. It has been shown that B. paravirosa strain isolated
from human feces is able to produce butyric acid from glucose [91]. Genes associated
with multiple pathways of butyrate production has been reported to be present in an
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isolate of B. paravirosa collected from chicken cecum [92]. These evidence corroborate
the screening of butyrate production ability of the B. paravirosa strain in this study.
Interestingly the genus Butyricimonas was reported to be decreased in altered gut
microbiota of patients with multiple sclerosis (MS) [93]. The lower abundance of
Butyricimonas paravirosa in the gut microbiome of a cohort of Australian children, with
islet autoimmunity who did or did not progress to diabetes, or with recent-onset of T1D
in relation to sibling and unrelated controls, also indicate the relevance of this bacteria in
the prevention of metabolic diseases as well. Interventions like targeted probiotics that
can restore the balance of gut microbiome could be a promising therapeutic strategy to
slow or halt the development of disease like T1D [94].
Genus Coprococcus includes anaerobic Gram-postive cocci that produce butyric
acid from the fermentable carbohydrate. Coprococcus comes is an obligate anaerobic
species coming under this genus that can produce butyrate in PY medium containing
either glucose or pyruvate [95]. The genomic potential of this species to produce butyrate
has previously been reported based on the detection of molecular markers such as buk
[61]. Genus Coprococcus has negative association with Crohn’s disease (CD), a
phenotype of IBD. A culture independent analysis using 16s rRNA gene sequencing of
ileal mucosa samples from patients with ileal CD has shown a significant lower level of
Coprococcus when compared to healthy control [96]. Corroborating this, a highresolution analysis using shot gun metagenome sequencing identified Coprococcus
comes as a biomarker species that decreased in CD patients[97].
Megasphaera indica is an obligate anaerobic Gram-negative coccus. Although it
is a non-motile and non-spore forming bacteria that can produce n-caproic acid as the
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major SCFA, it can also produce minor amounts of n-butyric acid [98]. It is a member of
human gut microbiome with scarce information available about its role in gut
homeostasis and association with diseases [99].
Agathobaculum butyriciproducens is another strict anaerobic and butyrate
producing bacterium from the phylum Firmicutes. The potential of this bacteria as an oral
bacteriotherapeutic to enhance the cognitive function and to ameliorate the Alzheimer's
disease (AD) has been explored in animal models [100]. This finding supports the
selection of this bacteria in this study to explore its beneficial properties as a butyrate
producer.
The above facts of selected four butyrate-producing bacteria show that microbial
alteration by enriching these bacteria might be a therapeutic strategy for several gut
related disease. However, using mouse as an animal model to study the host -microbe
interaction and therapeutic effect needs to be investigated as these bacteria are from
human gut. Successful colonization of these bacteria in the mouse gut proves the use of
mouse as animal model to study these bacteria.
2.3.3

Abundance of selected bacterial strains in the individual and pooled donor
sample
To see whether selected strains were present in all the donor samples and how

their abundance was represented in the individual and pooled samples, an abundance
mapping was performed using whole genome sequence data of the donor stool
metagenomic samples. Interestingly, all the four bacteria were detected in all the six as
well as pooled donor samples. Butyricimonas paravirosa (Odoribacteraceae) showed a
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higher abundance of more than 10% compared to other three bacteria the abundance of
which were less than 5% (Figure 5). All the four bacteria were consistently detected in all
the donor samples indicating these bacteria may be representatives of human core
microbiota.

Figure 5. Abundance of selected bacterial strains in the donor stool samples.

2.3.4

Colonization fitness of the selected bacteria in the mouse gut when
introduced as complex microbiota.
Fecal microbiota transplantation (FMT) has been successfully used as a

therapeutic strategy against recurrent Clostridium difficile infection (CDI). It is an
alternative to antibiotic treatment for the management of several gastrointestinal disorders
and recommended for conditions such as IBD, autoimmune disorders, metabolic and
certain allergic disorders [101, 102]. However, modest efficacy of FMT , as a clinical
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therapy to chronic disorders that are associated with microbial dysbiosis like IBD, and
higher variability in patient response show the need of more refined FMT formulations
for long term application [8]. The selection of donor is a key factor of FMT success, and
the microbial diversity of the donor intestinal microbiota has major influence in the
success of FMT. The donor microbiota richness and the composition are reliable
predictors of FMT success [8, 103, 104]. Clinical efficacy of FMT for IBD has been
found correlated with presence and response of key microbial signatures in donors and
patients, respectively. Specific members of Clostridium clusters IV and XIVa that mostly
include genera from the Ruminococcaceae and Lachnospiraceae family have been shown
to increase their relative abundance in the responding patients following FMT.
Furthermore, increased butyrate production by the members of Clostridium clusters
IV and XIVa has been associated with prolonged remission [8, 103, 105, 106]. Notably,
enrichment of specific members of these clusters, especially Ruminococcaceae and
Lachnospiraceae families in the donor stool shown to be more successful in the remission
of IBD following FMT [106, 107]. Thus, transferring high levels of key stone species like
butyrate producers as in case of IBD treatment may be important for therapeutic
restoration of gut homeostasis in dysbiotic individuals.
More than a clinical remedy, FMT has been used as an incredible tool to create
high-fidelity replicates of the human gut microbiota that is, humanized gnotobiotic mouse
model. This mice model, generated by the fecal microbiota transplantation of human
feces to germ free mice, mimic human gut microbial ecosystem as it recapitulates
phylogenetic composition of human gut microbiota to a large extent. Humanized
gnotobiotic mouse model thus serves as an innovative and powerful tool in the gut
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microbiota research [108, 109]. Although the structure and diversity of the human fecal
microbiota can be preserved remarkably, some of the resident bacterial taxa in the human
gut microbiota may not establish in the humanized gnotobiotic mice model after FMT
[108, 110]. Few reasons for this could be the new host itself with which it has not coevolved [108], or the competitive inability of those bacteria to survive and establish in the
new host when introduced as a part of complex microbiota. The second reason is more
important here as because the efficiency of the selected bacteria in this study to establish
competitively in a niche would make them as important candidate members of the donor
fecal microbiota or defined bacterial mix for clinical therapies.
Thus, to understand the competitive fitness and to use mice as a model to
elucidate the host-microbe interaction of selected butyrate-producing bacteria, we
transplanted the original pooled fecal sample, used for isolation of these bacteria [86],
into germ free mice. To make sure that these bacteria are reliably transmitted from
mothers to their offspring and stably remained as a part of the established community
over generations, fecal samples of hFMT mice after several generations were collected
and analyzed. Identification and classification of the microbes, without the use of
culturing technique, can be performed by sequencing of the 16s ribosomal RNA (rRNA)
genes present in an ecosystem [110]. Portions of the variable region 3 (V3) to variable
region 4 (V4) of bacterial 16S rRNA genes were amplified and sequenced to characterize
the taxa present in the gut microbial community of the hFMT mice. Since the focus of
this study is to identify the presence of four selected bacteria, community profiling was
performed using a custom database in qiime2 [88].
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Interestingly, presence of all four bacteria with varying relative abundance was
found in the fecal samples of hFMT mice after several generations (Figure 6). Highest
abundance was showed by Butyricimonas paravirosa SG-1991 form the phylum
Bacteroidetes followed by members of the phylum Firmicutes. Lowest abundance was
showed by Megasphaera indica SG-518. This indicates that these bacteria can colonize
in the mouse gut even when introduced as a part of complex community. Competitive
ability of these bacteria to be a part of assembled community makes these bacteria better
candidates for donor microbiota used for FMT or defined bacterial consortium as
therapeutics for clinical conditions. Furthermore, their successful transference form
mothers to offspring in an experimental set up for several generations proves that mice as
a good model for the host microbe interactions of these four bacteria.
Engraftment of important key species after FMT is a critical step in the success of
FMT treatment [8]. For the successful engraftment, individual species has to face several
barriers from both host and microbial side. Competition with members of the donor
community as well as resident community will be some of such barrier factors. Pooling
of stool samples from several donors make the donor fecal microbiota more diverse and
has been used as one of the successful FMT treatment strategy [111]. Increased species
richness also makes the competition of individual species in the donor microbiota to
engraft in the host more difficult. Results of this experiment thus show that selected
butyrate producers are competent enough to engraft in the host without displaced at least
by other members of the pooled donor microbiota.
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2.3.5

Effect of diet, disease, and antibiotics on the colonization stability
Diet change, disease and antibiotics are major disturbances that cause disruption

to a stable gut microbiota community. Substantial shift in the microbial communities to
an alternative stable state is possible with these disturbances and the disruption of stable
state depends on the resilience of the community to a type of perturbation [112]. Both
short-term and long-term diet change can cause statistically significant changes in the gut
microbiota [112-114]. Antibiotic treatment is a large disturbance to gut microbiota that
can move the microbiota to an alternative stable state [112]. This stable state, reached by
the microbiota after antibiotic treatment, is distinct from pretreatment state and the shift
in the microbiota state can persists for years [115-117]. Similarly, physiological state of
the host also affects the composition of the microbiota [112]. From the healthy state,
compositional and functional deviations of microbiota in disease conditions have been
reported by several previous studies [118, 119]. A correlation between alterations in fecal
microbiome community structure and function with several gastrointestinal diseases also
evident from previous studies [112, 120-123].
To prove the hypothesis that, once established the colonization stability of
selected four butyrate producers will not be altered by disturbances such as change in
diet, disease condition, and antibiotic treatment, hFMT mice were either treated with
inulin, DSS, or antibiotic. Inulin is a complex carbohydrate, supplementation of which in
drinking water will change the normal diet to a high fiber diet. Fecal samples were
analyzed for bacterial community profiling using 16s rRNA sequencing immediately
after a sudden change in the diet by supplying inulin for three days. As expected only a
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minor change happened in response to diet change, where the relative abundance of the
selected four bacteria altered but none got displaced (Figure 6).
Because of the many similarities to human ulcerative colitis, DSS induced colitis
in mice is a widely accepted chemical induced colitis to study IBD pathogenesis [124].
Analysis of bacterial community in the fecal sample immediately after induction of colitis
by DSS (2.5%) in drinking water for 5 days showed not much shift in the relative
abundance of the selected four bacteria in hFMT mice (Figure 6).
This indicates that once established these bacteria are less prone to the minor
perturbances caused by diet change and disease condition. Diseases like IBD has been
shown to be associated with lose of butyrate producers. While results of this study shows
that there are butyrate producers that are less affected by change in physiological state of
the host, and hence their presence in the host may paly role in the remission of disease via
butyrate synthesis. In the therapeutic point of view, presence of these bacteria in the
donor feces (as in case of FMT) or in the defined bacterial mix (as in the case of MET),
may increase the success of the treatment.
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Figure 6. Stable colonization of selected butyrate producers in the mouse gut. Stacked bar
plot shows the relative abundance of four selected butyrate-producing bacteria in the
fecal samples of mice several generations after pooled microbiota transplantation. All
four bacteria were found in the untreated, inulin treated and DSS treated mice, while only
two bacteria were able to withstand the perturbances caused by the antibiotic treatment.
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2.4 Conclusion
………………………………………………………………….
To circumvent the drawbacks and limitations of FMT, use of defined bacterial
consortium has been proposed as one of the therapeutic approaches. Mining of beneficial
gut bacterial species and defining their combination are various steps in the effort of
developing such consortia based bacterial therapeutics. This study contributing to this
broad effort by selecting few under explored bacteria to derive a simple therapeutic
consortium. Keeping the potential of butyrate production as the selection criteria, four
human gut bacteria were selected after screening for their genotypic and phenotypic
potential for butyrate production. Stable colonization of these bacteria in the mouse gut
reveals the use of mouse as a good animal model for the further elucidation of host
beneficial properties of these bacteria. The competitive fitness of these bacteria to
establish in the gut when introduced as a part of complex microbiota further proves their
key membership in a simple or complex fecal microbiota for the successful therapies.
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CHAPTER 2. ASSESSMENT OF COLONIZATION AND HOST HEALTH
BENEFITS BY A DEFINED CONSORTIUM OF FOUR BUTYRATE
PRODUCING HUMAN GUT BACTERIA IN GNOTOBIOTIC MOUSE MODEL

3.1 Introduction
……………………………………………………………….
Defined synthetic microbial community study has its own advantages as
compared to studies using complex microbiota. Defined communities of known
composition often give us a better understanding of the interactions of gut species and
community assembly and dynamics. Its more challenging to use the complex microbiota
like fecal material to delineate the community member interactions and their role in
community assemblage because of the high complexity, inter individual variability, and
the presence of unidentified and non-sequenced microbial members. Several studies have
used defined synthetic communities either in-vitro [125-127] or in-vivo [128] model
systems to exploit this reductionist approach. However, if we consider the host – microbe
interactions like host immune modulation by the gut microbial community, use of in-vivo
models would be the best approach. A widely used in-vivo experimental model to study
the properties of a defined community in a living system is the use of gnotobiotic
animals. For example, to understand the effect of dietary interventions on microbiota
composition changes Becker et al used gnotobiotic rats colonized with eight species of
human gut bacteria [129]. To study microbe -microbe interactions or microbe, diet and
host interactions other researchers have used mice colonized with defined human bacteria
[130, 131]. In a very recent study gnotobiotic mouse colonized with ten representative

40
species of the human intestinal microbiota was used to understand the effect of diet
induced changes in the gut microbiota on host metabolism in parallel to microbial gene
expressions [128]. In another study mice colonized with defined consortium of 11 healthy
human-associated bacterial strains were used to study host-microbe interactions and
showed that these species act in concert to induce IFNγ+ CD8 T cells, confer resistance
to the intracellular pathogen Listeria, and effective at inhibiting tumor growth [84]. These
entire studies highlight the effectiveness of using simple defined microbial communities
in living systems to elucidate the interactions between host, diet and gut microbiome.
Short chain fatty acids (SCFA) are the major metabolic products of anaerobic
fermentation by microbial communities that colonize the mammalian gut. The main
SCFA produced by the gut microbiota include butyrate, acetate and propionate. These
microbial products especially propionate and butyrate, exert a range of health-promoting
functions. They are taken up efficiently by the gut mucosa and have important impacts
upon host physiology as sources of energy, as regulators of gene expression and as
signaling molecules that are recognized by specific receptors [132]. Butyrate in particular
has an important role in the metabolism and normal development of colonic epithelial
cells and has been implicated in protection against cancer and ulcerative colitis. Butyrate
is preferentially transported by gut epithelial cells, serves as a preferred energy source for
colonocytes, and has been shown to exert direct effects upon gene expression in
mammalian cells [133]. It has been demonstrated that the butyrate, which is secreted in
high amounts by commensal bacteria, can modulate the function of intestinal
macrophages, the most abundant immune cell type in the lamina propria. It has been also
shown that microbial-derived butyrate exerts anti-inflammatory properties as well as
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differentiation of Treg cells in the colon and thereby establish immunological
homeostasis in the gut [51, 134, 135]. The butyrate production in the gut mainly depends
upon the presence of butyrate producers in the gut microbiota community. Although this
was influenced by the factors like diet and host genetics, the imbalance in the gut
microbiota that leads to decrease in the butyrate producers have several implications in
the normal host physiology as well as in the pathogenesis of disease conditions like
Diabetes mellitus [21-23].
Considering the above-mentioned facts – importance of a defined synthetic and
simplified community and the beneficial role of butyrate, the objective this project was to
formulate a simple consortium of 4 human gut bacteria (BPC – Butyrate-producing
consortium) that have the potential ability to produce butyrate. We focus on the assembly
and the colonization dynamics of this community in germ free mouse gut in relation to
pathways of butyrate production and taxonomical features. Keeping the diet fixed, the
short chain fatty acid production of these members as a community was analyzed to see
their collaborative effort in case of butyrate production. The way this community
interacts with its host, directly or indirectly (through metabolites), and modulates the host
immunity has also been assessed to understand the beneficial effects of this community.
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3.2 Materials and methods
……………………………………………………………….
3.2.1

Bacterial culture and maintenance
All the selected four bacteria were cultured and maintained in an anaerobic

chamber (Coy) using DSMZ’s modified PYG media. Optical density (OD600) of
overnight grown cultures were adjusted to one and then aliquots were stored in 12%
DMSO at -80oC until use. To prepare inoculum equal volume of all four bacteria were
resuspended and then washed in PYG media. After centrifugation at 7000 RPM for 10
minutes, the bacteria pellets were reconstituted again in PYG media in small volume, i.e.,
1 ml of original culture to 50uL. Enough volume of bacterial suspension was prepared
and transferred to sterile 2mL glass vials and sealed airtight. Bacterial suspensions were
then stored at 4oC until transferred to GF mice units.
3.2.2

Gnotobiotic mice experiment
The basic concept of this research is to understand the properties of a simple

synthetic community of butyrate producing bacteria selected from a library of human gut
bacteria. Giving an equal opportunity, a mix of 4 selected bacteria (here onwards named
as ‘BPC - Butyrate producing consortium’) at equal proportions were inoculated into
germ free mice (Figure 7). The effect of this bacterial mix, both in case of microbial side
and host side, are then evaluated using different methodologies and the results were
compared against control group of germ-free mice without any treatment.
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Figure 7. Experimental concept. The cartoon shows the concept of the experiment where
a consortium of four selected butyrate producers from the human gut is introduced into
germ free mice. The immunological as well as physiological responses elicited in the
gnotobiotic mice were then assessed in comparison to germ free mice.

To study the microbial effects on the host by the selected butyrate producing
human gut bacteria, germ free mice were used as the in-vivo animal models. Six-weekold C57BL/6 germ free mice were purchased from Taconic Biosciences Inc. All animal
experiments were performed with the prior approval of the protocol (19-014A) by South
Dakota State University (SDSU) animal studies committee and under the regulations of
Institutional Animal Care and Use Committee (IACUC), SDSU policies. A total of 18
mice, including both male and female mice, were used for the experiment. A group of 12
mice with an equal number of male and female mice were used for bacterial treatment
and the remaining 4 mice were used as GF control group. Male and female mice were
caged separately. All mice were maintained in ad-libitum autoclaved normal chow diet
and potable drinking water under strict 12-hour light and dark cycles.
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Mice in the treatment group were orally gavaged with 200uL bacterial mix prepared as
mentioned above. A total of two inoculations per mouse were given (one/day/mouse) and
observed for 28 days (Figure 8). Fecal samples were collected at different time points
starting from 48 hours after second inoculation. All mice including control group GF
mice were euthanized after 28 days by cervical dislocation and samples were collected
for further analysis.

Figure 8. Experimental outline. Microbial consortium of four human gut bacteria was
introduced to germ free mice by oral gavaging. After a total of two inoculations (one per
day), the bacteria were allowed to colonize for 28 days after which the animals were
sacrificed to collect samples.

3.2.3

Total RNA extraction from tissue
To assess the localized response of host-microbe interaction resulted by the

colonization of BPC, 100mg tissue from the colon was sampled and snap frozen in liquid
nitrogen. The samples were then saved at -80oC until further processing. For RNA
extraction, individual tissue samples were transferred to a pre-cooled mortar and
homogenized using a pre-cooled pestle. Thawing of the tissue was prevented by
maintaining the temperature with the help of liquid nitrogen. Once homogenized 1mL of
TRIzol® reagent (ambion, life technologies) was added to mortar with homogenized
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tissue. Tissue was mixed with TRIzol reagent and then transferred to an Eppendorf tube.
To ensure proper lysing of the tissue, the tissue lysate was pipetted several times until
there was no visible chunk of tissue. After homogenization for 5 minutes, tissue lysate in
TRIzol was treated with chloroform (Sigma-Aldrich) followed by precipitation with
isopropanol (Fisher Bioreagents). Washing of the precipitated RNA was performed using
freshly prepared 80% molecular grade ethanol. After washing the RNA pellet was dried
by evaporating excess alcohol. Once the ethanol was removed, the pellet was
resuspended in 50uL UltraPure Distilled nuclease free water (Invitrogen). The quality and
the quantity of the RNA was evaluated using NanoDrop One (Thermoscientific) as well
as visualizing on an agarose gel. Total RNA extracted was saved at -80oC.
A DNAse treatment was performed on the RNA extracted before using for cDNA
synthesis. RNase-Free DNase set (Qiagen) was used to remove any contaminant genomic
DNA using the kit according to manufacturer’s protocol. Briefly, 10uL Buffer RDD and
2.5 uL DNase I stock solution was added to ≤ 87.5 uL RNA solution and then the volume
made up to 100uL with RNase-free water. The reaction mixture was incubated at 20-25oC
for 10 min. After DNase treatment, RNA was again precipitated using isopropanol and
then cleaned as mentioned in the extraction protocol. Further evaluation of RNA quality,
quantity and integrity were assessed again by NanoDrop One and agarose gel
visualization.
3.2.4

Gel electrophoresis
One percentage agarose gel was prepared in TAE buffer by adding 1g Agarose I

(Thermo scientific) in 100mL TAE buffer. To prepare buffers, Diethyl pyrocarbonate
(DEPC, Sigma-Aldrich) treated water was used. For DEPC treatment, 1 mL of DEPC
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was added to 1L of autoclaved MilliQ and incubated overnight at 37oC. Deactivation of
the DEPC was performed by autoclaving treated water at 121oC for 15 minutes. Before
preparing the gel, all gel apparatus were cleaned with RNAse AWAY (Thermo
scientific). RNA samples were mixed with RNA loading dye prior to gel loading and the
electrophoresis was performed at 80 v, 400 mA and for 40 minutes. The integrity of the
RNA was then visualized under Ultra-Violet (UV) lamp.
3.2.5

cDNA preparation
Complimentary DNA (cDNA) was prepared from 250 ng of DNAse treated total

RNA using First strand cDNA synthesis kit (New England BioLabs Inc (NEB #M0368))
as per manufacturer’s protocol. Details of the items needed for cDNA synthesis are
provided in Table 4.

Table 4. The list of components used in the preparation of cDNA
Material

Cat Log Number #

Oligo d(T)23VN

S1327S, NEB

10 mM dNTP

N0447S, NEB

ProtoScript® II Reverse Transcriptase

M0368L, NEB

RNase Inhibitor

M0314S, NEB

Nuclease free water

10977, Invitrogen

Briefly, a total of 250 ng of RNA was mixed with 2uL of 50uM Oligo d(T)23 and
1uL of 10mM dNTP and the volume made up to 10uL using nuclease free water. The
RNA was denatured for 5 minutes at 65oC. 4uL of 5X ProtoScript II Buffer, 2uL of 0.1 M
DTT (Dithiothreitol), 1uL of ProtoScript II RT (200 U/µl), 0.2uL of RNase Inhibitor (40

47
U/µl) and 2.8uL of nuclease free water was added to the reaction mixture. The 20uL
reaction mixture was incubated at 40oC for one hour followed by inactivation of enzyme
at 65oC for 20 minutes. The volume of reaction mixture was then made up to 110uL by
adding 90uL of NFW and stored at -20oC until further use.
3.2.6

Quantitative RT-PCR based Gene expression profile using RT2 profiler
PCR-arrays

Since this is an exploratory study where the immune responses of the host to the
members of the BPC were unknown, an untargeted approach was used. To assess the host
immune responses, expressions of 88 genes in the colon tissue were screened using qRTPCR. Reaction mixture was prepared as per RT2 profiler PCR array protocol (Qiagen)
where a mix for 96 well plate was prepared by adding 1350uL of Power SYBR® Green
PCR Master mix (Applied Biosystems), 102uL cDNA synthesis reaction and 1248uL of
RNase-free water. A volume of 25uL was then added in to each well of the 96 well plate
containing the prefilled primer pairs. The plate was sealed with Optical thin wall 8 cap
strips (Qiagen) and centrifuged at 1000RPM for 1 min to remove bubbles. The PCR
cycles (
Table 5) were run in ABI7500 standard (Applied Biosystem) RT-PCR machine using the
following cycling conditions:
Table 5. Thermal cycler conditions used for RT-PCR
Stage
1
2

Cycles
1
40

Duration
10 min
15s
1 min

Temperature
95oC
95oC
60oC
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Raw cycle threshold (CT) values at a threshold of 0.15 were exported and then
uploaded to Qiagen data analysis center for further analysis. A CT cut-off value of 30 was
set for analysis. An average geometric mean of CT values of two housekeeping genes mouse beta actin (Actb) and mouse glyceraldehyde phosphate dehydrogenase (Gapdh)
were used for data normalization and ΔCT calculation. Fold change and fold regulation in
the gene expression were calculated using ΔΔCT method.
Table 6. List of genes screened for their expression in the colon to assess the effect of
bacterial colonization on the host.
Refseq
NM_013605
NM_023566
XM_006504541

Symbol
Muc1
Muc2
Muc3

NM_172729

Nod1

NM_145857
NM_030682
NM_011905
NM_021297
NM_016928
NM_011604
NM_133211
NM_133212
NM_031178
NM_205819
NM_205823
NM_205820

Nod2
Tlr1
Tlr2
Tlr4
Tlr5
Tlr6
Tlr7
Tlr8
Tlr9
Tlr11
Tlr12
Tlr13

NM_010851
NM_010554
NM_008361

Myd88
Il1a
Il1b

Description
Mucin 1, transmembrane
Mucin 2
Mucin 3, intestinal
Nucleotide-binding
oligomerization domain
containing 1
Nucleotide-binding
oligomerization domain
containing 2
Toll-like receptor 1
Toll-like receptor 2
Toll-like receptor 4
Toll-like receptor 5
Toll-like receptor 6
Toll-like receptor 7
Toll-like receptor 8
Toll-like receptor 9
Toll-like receptor 11
Toll-like receptor 12
Toll-like receptor 13
Myeloid differentiation primary
response gene 88
Interleukin 1 alpha
Interleukin 1 beta

RT2 Catalog
PPM03608A
PPM24739G
PPM25412A

PPM27293C

PPM33810B
PPM04211B
PPM04220B
PPM04207F
PPM04206E
PPM04210B
PPM04208A
PPM04213E
PPM04221A
PPM06270A
PPM41001A
PPM41490A
PPM03399A
PPM03010F
PPM03109F
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NM_008366
NM_021283
NM_010558
NM_001314054
NM_010548
NM_008351
NM_001303244
NM_008355
NM_010552
NM_019508
NM_008360
NM_021380
NM_016971

Il2
Il4
Il5
Il6
Il10
Il12a
Il12b
Il13
Il17a
Il17b
Il18
Il20
Il22

NM_031252
NM_080729
NM_145636
NM_013693

Il23a
Il25
Il27
Tnf

NM_011577

Tgfb1

NM_008689

Nfkb1

NM_019408
NM_010507
NM_010510
NM_008337

Nfkb2
Ifna9
Ifnb1
Ifng

NM_011259

Reg3a

NM_011036

Reg3b

NM_011260
NM_020509
NM_023881
NM_010031
NM_001167790
NM_007843
NM_010030
NM_013756
NM_019728
NM_030734

Reg3g
Retnla
Retnlb
Defa1
Defa17
Defb1
Defb2
Defb3
Defb4
Defb5

Interleukin 2
Interleukin 4
Interleukin 5
Interleukin 6
Interleukin 10
Interleukin 12A
Interleukin 12b
Interleukin 13
Interleukin 17A
Interleukin 17B
Interleukin 18
Interleukin 20
Interleukin 22
Interleukin 23, alpha subunit
p19
Interleukin 25
Interleukin 27
Tumor necrosis factor
Transforming growth factor,
beta 1
Nuclear factor of kappa light
polypeptide gene enhancer in Bcells 1, p105
Nuclear factor of kappa light
polypeptide gene enhancer in Bcells 2, p49/p100
Interferon alpha 9
Interferon beta 1, fibroblast
Interferon gamma
Regenerating islet-derived 3
alpha
Regenerating islet-derived 3
beta
Regenerating islet-derived 3
gamma
Resistin like alpha
Resistin like beta
Defensin, alpha 1
Defensin, alpha, 17
Defensin beta 1
Defensin beta 2
Defensin beta 3
Defensin beta 4
Defensin beta 5

PPM02937C
PPM03013F
PPM03014F
PPM03015A
PPM03017C
PPM03019A
PPM03020E
PPM03021B
PPM03023A
PPM03540A
PPM03112B
PPM03541B
PPM05481A
PPM03763F
PPM05427F
PPM33809A
PPM03113G
PPM02991B

PPM02930F

PPM03204G
PPM03544A
PPM03594C
PPM03121A
PPM24824A
PPM24825A
PPM35204A
PPM03005F
PPM05091A
PPM37773A
PPM63552A
PPM25297F
PPM28936A
PPM30650F
PPM29171A
PPM34137A
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NM_181683
NM_183038

Defb37
Defb39

Defensin beta 37
Defensin beta 39
Bactericidal permeablility
NM_177850
Bpi
increasing protein
NLR family, CARD domain
NM_001033367 Nlrc4
containing 4
NLR family, pyrin domain
NM_145827
Nlrp3
containing 3
NLR family, pyrin domain
NM_001081389 Nlrp6
containing 6
NLR family, pyrin domain
NM_001033431 Nlrp12 containing 12
NM_009807
Casp1
Caspase 1
Cathelicidin antimicrobial
NM_009921
Camp
peptide
NM_013653
Ccl5
Chemokine (C-C motif) ligand 5
Chemokine (C-C motif) ligand
NM_016960
Ccl20
20
Chemokine (C-C motif) ligand
NM_009138
Ccl25
25
Chemokine (C-C motif) ligand
NM_020279
Ccl28
28
Chemokine (C-X-C motif)
NM_008176
Cxcl1
ligand 1
Chemokine (C-X-C motif)
NM_018866
Cxcl13 ligand 13
Bactericidal permeablility
NM_177850
Bpi
increasing protein
S100 calcium binding protein
NM_013650
S100a8 A8 (calgranulin A)
S100 calcium binding protein
NM_009114
S100a9 A9 (calgranulin B)
NM_054039
Foxp3
Forkhead box P3
NM_016674
Cldn1
Claudin 1
NM_008756
Ocln
Occludin
NM_009864
Cdh1
Cadherin 1
NM_009386
Tjp1
Tight junction protein 1
Fatty acid binding protein 2,
NM_007980
Fabp2
intestinal
Solute carrier family 16
(monocarboxylic acid
NM_009196
Slc16a1 transporters), member 1
Solute carrier family 5 (iodide
NM_145423
Slc5a8 transporter), member 8
NM_146187
Ffar2
Free fatty acid receptor 2

PPM36272A
PPM58991A
PPM35806A
PPM31278A
PPM29506F
PPM26688B
PPM37047B
PPM02921E
PPM25023A
PPM02960F
PPM03142B
PPM02972F
PPM03603C
PPM03058C
PPM02947G
PPM35806A
PPM05051F
PPM05050E
PPM05497F
PPM05454A
PPM05314A
PPM03652F
PPM25091A
PPM27271A

PPM25515A
PPM29969B
PPM04863A
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NM_001033316
NM_030701
NM_011038
NM_013627
NM_013685
NM_008100
NM_011831
NM_145435

3.2.7

Ffar3
Niacr1
Pax4
Pax6
Tcf4
Gcg
Insl5
Pyy

Free fatty acid receptor 3
Niacin receptor 1
Paired box gene 4
Paired box gene 6
Transcription factor 4
Glucagon
Insulin-like 5
Peptide YY

PPM59038A
PPM03781A
PPM05533A
PPM04498B
PPM05459C
PPM04763G
PPM30485A
PPM29314B

Lymphocytes separation from mouse PBMC
Immediately after euthanasia, blood was collected via cardiac puncture and

immediately transferred to a heparinized blood collection vials (BD Vacutainer) and
gently mixed to avoid any coagulation. SepMate TM PBMC isolation tubes (STEMCELL
Technologies) were used for collection of lymphocytes from the blood. Equal volume of
DPBS (Dulbecco’s PBS) was added to blood sample before transferring to the SepMate
TM

tubes prefilled with 4.5 mL of Lymphoprep (STEMCELL Technologies) density

gradient medium. Tubes were then centrifuged at 1200 x g for 10 minutes at room
temperature. The top layer containing the plasma and the mononuclear cells (MNC) was
transferred to a fresh 15mL falcon tube by a single pour off step. After washing two times
with DPBS, transferred MNCs were then re-suspended in freezing media containing 10%
DMSO and stored in liquid nitrogen.
3.2.8

Lymphocytes separation from mouse spleen
Mechanical disruption was used to separate lymphocytes from spleen. After

removing the capsular layer, the tissue was disrupted using sterile BP blades and the cell
suspension in RPMI1640 media (Corning) was filtered through a cell strainer (70uM
Nylon mesh, Fisherbrand) to make single cell suspension. Cells were washed in RPMI
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1640 (Corning) one time and then treated with ammonium chloride solution
(STEMCELL Technologies) at 9 :1 ration with RPMI 1640 cell culture media for 7
minutes on ice to lyse RBCs. After lysing RBCs, the cells were washed twice with RPMI
1640 media and resuspended in freezing media containing 10% DMSO and stored in
liquid nitrogen until further use.
3.2.9

Flowcytomtery
Frozen lymphocytes collected from peripheral blood and spleen were thawed and

then washed twice with RPMI 1640 (Corning) media. Cell counts were performed for
each sample using Trypan blue staining method in Cell countess (Thermofisher). On an
average 10^5 – 10^7 cells were used per well of a U bottom 96 well plate. Profiling of
immune cell populations was performed using two panels of multicolor cell staining
(Figure 9).
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Figure 9. Cell staining panels used for immune cell profiling using flow cytometry.
Details of the two panels of cell staining used for profiling the immune cell populations
in the spleen and PBMC.
The procedure involved three major steps. In both panels, viability dye staining
was performed as the first step to select only the viable cells in the collected cell
population. Cell surface target staining was the second step, which was then followed by
intracellular antigen staining. Finally, stained cells were fixed in IC fixation buffer
(Thermofisher) and analyzed on the flow cytometer within 48 hours of staining. Details
of the antibody and the fluorochromes used are shown in Table 7 and Table 8. All the
staining procedures were performed according to manufacturer’s protocols.
Table 7. List of antibodies with flourochrome used for staining the immune cells under
panel 1.
Fluorochrome
FITC

Antigen
CD45

PE

Cell type
Lymphocyte
s total
B cells

PE-Cyanine7

Tgd

TCR
gamma/delt
a

APC

ILC3

ROR
gamma (t)

Alexa Fluor 700

Tab

TCR beta

LIVE/DEAD
Fixable Near-IR
Dead Cell Stain

Live cells

-

CD19

Clone
30-F11

Product
CD45 Monoclonal Antibody (30F11), FITC, eBioscience™
eBio1D3 CD19 Monoclonal Antibody
(1D3)
(eBio1D3 (1D3)), PE,
eBioscience™
eBioGL TCR gamma/delta Monoclonal
3 (GL-3, Antibody (eBioGL3 (GL-3,
GL3)
GL3)), PE-Cyanine7,
eBioscience™
AFKJS- ROR gamma (t) Monoclonal
9
Antibody (AFKJS-9), APC,
eBioscience™
H57-597 TCR beta Monoclonal Antibody
(H57-597), Alexa Fluor 700,
eBioscience™
LIVE/DEAD™ Fixable Near-IR
Dead Cell Stain Kit, for 633 or
635 nm excitation
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Table 8. List of antibodies with fluorochrome used for staining immune cells under panel
2.
Fluorochrome
FITC

Antigen
CD45

Clone
30-F11

PE

Cell type
Lymphocyte
s total
CD8 cells

CD8

53-6.7

PE-Cyanine5.5

CD4 cells

CD4

RM4-5

PE-Cyanine7

Treg

FOXP3

APC

Th17

Alexa Fluor 700

Tab

ROR
gamma
(t)
TCR
beta

FJK16s
AFKJS9

LIVE/DEAD
Fixable Near-IR
Dead Cell Stain

Live cells

-

H57597

Product
CD45 Monoclonal Antibody (30F11), FITC, eBioscience™
CD8a Monoclonal Antibody (53-6.7),
PE, eBioscience™
CD4 Monoclonal Antibody (RM4-5),
PE-Cyanine5.5, eBioscience™
FOXP3 Monoclonal Antibody (FJK16s), PE-Cyanine7, eBioscience™
ROR gamma (t) Monoclonal
Antibody (AFKJS-9), APC,
eBioscience™
TCR beta Monoclonal Antibody
(H57-597), Alexa Fluor 700,
eBioscience™
LIVE/DEAD™ Fixable Near-IR
Dead Cell Stain Kit, for 633 or 635
nm excitation

After staining, the cells were injected into a Attune NxT Flowcytometer
(Thermofisher) for analysis. Compensation was performed using compensation beads
(Thermofisher) stained with individual dye. Unstained beads were used as a negative
control for compensation. To obtain the percentage of different cell populations,
achieving approximately ten thousand CD45+ cells was the cut off for the number of
events collected per sample. Since there was not enough cells in the PBMC samples, the
cutoff was reduced accordingly. The raw FCS file were then further analyzed in FlowJo
software. See Figure 10 and Figure 11 for a pictorial representation of gating strategies
used to analyze the samples.
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Figure 10. Gating strategy used for profiling different populations of lymphocytes under
panel 1.
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Figure 11. Gating strategy used for profiling different populations of lymphocytes under
panel 2.
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3.3 Results and Discussion
……………………………………………………………
A mono-colonization approach would give us understanding of a single bacterium
in a host but the result cannot be used to predict the properties of the same bacteria when
in a community. Complex interactions and similar functional properties make it difficult
to figure out the role of individual bacteria in a complex community. The advantage of a
simple consortium is that it would help us to elucidate the role of a bacterium by the
bottom-up community assembly approach or by species deletion methods. Thus, to
understand the beneficial properties elicited by the selected human gut bacterial members
on the host, an in vivo mouse model was used and the bacteria were introduced as a
simple consortium to a previously unoccupied niche, that is mouse gut, by oral
inoculation. The use of a mouse model for studying these bacteria was verified in the
previous experiment (chapter 1) as these bacteria are allochthonous to mouse species.
After a total of two inoculations, bacteria were allowed to colonize for a period of 28
days. Fecal samples were collected for bacterial enumeration and 16s rRNA sequencing
at different time points starting after 48 hours post 2nd inoculation. After 28 days, animals
were euthanized, and samples were collected for further analysis.

3.3.1

Colonization and community formation in germ free mice
Total bacterial count in the fecal samples collected at different time points were

assessed to evaluate the bacterial load, which in turn indicates the colonization of the
bacteria. Anaerobic modified PYG media (DSMZ medium) was used to enumerate the
bacterial load as this media was found to be supportive for good growth for all four
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bacteria selected. An average bacterial load of >107 cfu/g feces was found from 4th DPI
and kept increasing until it reached >108 cfu/g feces (Figure 12) by the end of the
experiment. We could not find any dip in the bacterial load indicating a successful and
stable colonization of selected bacteria in the mouse gut. After euthanasia, the total
bacterial load in the cecal content was enumerated using the same media conditions under
anaerobic conditions. An average bacterial count of nearly 109 cfu/g was obtained from
cecal content (Figure 13) further validating the successful colonization of the bacteria in
the mouse gut.

Figure 12. Total bacterial load in the feces of gnotobiotic mouse. Line graph showing the
total viable bacterial load enumerated from the fecal samples of gnotobiotic mice
collected at different time points. The upward trend in the bacterial load without any
major dip indicates a stable colonization of human gut bacteria introduced in the mice
gut. (DPI – Day post inoculation).
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Microbial DNA extracted from the fecal and cecal contents was used for bacterial
community profiling using 16s rRNA gene sequencing. Taxonomic assignments in
qiime2 using greengene database as well as custom database showed presence of all four
bacteria in the emerged community inside the mouse gut (Figure 14). Two bacteria,
Butyricimonas paravirosa and Megasphaera indica, colonized in all the mice while
Agathobaculum butyriciproducens and Coprococcus comes showed only a partial
colonization in treated mice. The partial colonization of these bacteria was not associated
with the sex of the mice as it was found both in male and female mice. In most of the
treated mice highest mean relative abundance was showed by B. paravirosa. This result
was similar to its abundance in the human donor samples as well as in hFMT mice
(Figure 6). The bacteria with the second highest relative abundance were M. indica,
followed by Coprococcus comes.

Figure 13. Total viable bacterial load enumerated from the cecal contents. After
euthanasia, cecal contents were plated using serial dilution approach in anaerobic
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conditions. The bar plot showing the total bacterial load enumerated from the cecal
contents from the gnotobiotic mice after 28 days of post inoculation.
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Figure 14. Relative abundance of the BPC members in the cecal content of gnotobiotic
mice. Taxonomic assignments and the relative abundance of BPC members in the cecal
content of gnotobiotic mice were assessed by 16s rRNA gene sequencing and Qiime2
bioinformatics pipeline. Scatter plot of the relative abundance of members of BPC in the
gnotobiotic mice indicates successful colonization of all four bacteria in the cecum of
BPC treated mice.
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3.3.2

Butyrate and other SCFA production potential of emerged community
The hypothesis was that the in-vivo community would be able to produce butyrate

as one of the metabolites of their fermentative action. Interestingly, the colonized fraction
of the consortium was able to produce not only butyrate but other SCFA as well when
mice were fed with normal chow diet. Analysis of cecal content using GC detected all
SCFA, except acetate, in the BPC colonized mice at significantly different levels
compared to GF mice (Figure 15). Without any significant difference, acetate was
detected both in GF and colonized mice. Detection of SCFA at a level of <100uM
indicates that either these bacteria are not prolific producers of butyrate or other SCFA,
or there is a high uptake of these SCFA by the host.

Figure 15. SCFA profile in the cecal content of gnotobiotic mice in comparison to germ
free counterpart. Boxplot showing the levels of SCFA detected by gas chromatography.
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Except for acetate, all other SCFA were detected at significant different level in
gnotobiotic mice cecal content as analyzed by Welch’s t test using GraphPad prism v 9.0.

Dietary interventions such as supplementation of fermentable fibers may increase
the SCFA levels by these bacteria. However, these interventions are not acceptable in
some cases, for example immune mediated colitis, as the supplementation of certain
fibers cause surfeit production of butyrate and results in exacerbation of inflammation
[136]. Thus, commensal gut bacteria that can produce butyrate from a normal diet at
moderate levels might be potential prophylactic or therapeutic candidates for
inflammatory conditions of the gut. Interestingly, members of the BPC were found to be
less affected by the inflammatory condition and thus make them better candidates for
prophylactic or therapeutic interventions, but this needs to be validated by further
experiments using disease models.
3.3.3

Effect on the gut health by the colonization of BPC assessed by
histopathology
Histopathological analysis of the colon tissue after H&E staining showed normal

appearance in both GF and BPC colonized gnotobiotic mice without any disturbance in
mucosal architecture (Figure 16). However, some morphological modifications were
observed between two groups. Both villus length and crypt depth were increased in
gnotobiotic mice compared to GF controls. The submucosa and muscularis propria were
thicker than GF mice but without any pathological signs like submucosal edema.
Presence of neutrophils between crypt epithelial cells of some crypts were noticed in
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gnotobiotic mice but no crypt abscess was present. The presence of infiltrating
neutrophils indicates mild inflammation as result of bacterial exposure Absence of any
pathological signs such as marked neutrophil infiltration, cryptitis, crypt abscess,
submucosal edema, loss goblet cells, loci of ulceration indicates that these bacteria are
not harmful to the host. Above all intact polarized epithelial cell structure with increased
villus length and crypt depth in gnotobiotic mice indicates that these bacteria enhanced
development of colon mucosa.

Figure 16. Histomorphological comparison of colon tissue. Photographs showing the
colon tissue cross sections after H&E staining. A) Germ free mice colon B) Gnotobiotic
mice colonized with BPC.
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3.3.4

Modulation of the host immunology and physiology by the colonization of
BPC

Gene expression profile of colon tissue:
To understand the effect of BPC on host, total tissue gene expression was
assessed using qRT-PCR. In order to cover most of the genes related to host’s immune
responses as well as physiological responses we used Qiagen’s RT2 profiler arrays that
can accommodate 88 genes of interest in an array (Table 6). There were around 77 host’s
immune related genes and 12 genes that were related to host’s intestinal physiology. The
fold change and fold regulation in the expression of each gene of colonized mice (n=11)
were found in comparison to germ free mice (n=4) after normalizing the raw threshold
cycle (Ct) data with that of geometric mean of two housekeeping genes, beta actin (Actb)
and Glyceraldehyde-3-phosphate dehydrogenase (Gapdh).
Out of 88 genes screened, only 11 genes showed a significance difference
(p<0.05) in their expression in BPC colonized mice compared to control (Figure 17). But
since their fold change in expression was below 2, we cannot take those expressions as
biologically relevant or meaningful. There was a total of 8 genes that showed more than
two-fold change in their expression compared to control GF group. There was only one
gene in our qRT-PCR array that showed a two-fold reduction in the expression in
colonized mice group compared to germ free mice. Since there was a high inter
individual variability in the expression of these genes, a significant difference at a p value
of less than 0.05 was not found. However, an average fold change of more than two-fold
compared to the germfree mice group indicates that BPC colonization has some effect on
the host.
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Figure 17. Gene expression profile of 88 genes in the colon tissue. Volcano plot showing
the genes that are expressed differentially in the colon tissue samples compared to that of
GF control group. Red – over expressed more than two-fold change. Green – under
expressed more than two-fold change.

Effect of BPC on the first line of host’s immune defenses in the colon:
Mucin 1 (MUC1) and mucin 2 (MUC2) are two genes expressed more than two-fold in
BPC colonized mice compared to GF mice group (Figure 18). MUC1 is a cell surface or
membrane bound mucin in the GIT that is constitutively expressed by nearly all epithelial
cells. More than a physical barrier to microbes, MUC1 plays immense role in modulating
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the pathogen-induced inflammation [137]. It has been demonstrated that over expression
of MUC1 caused suppression of TLRs downstream signaling and thus resulted in antiinflammatory activity [138]. Since PCR array showed no significant change in TLRs and
MyD88 expression in colon, the up regulation of MUC1 by the colonization of BPC
might have resulted in the suppression of TLRs signaling and thus attenuated
inflammation.

Figure 18. Genes that are up or down-regulated more than two-fold change in the
gnotobiotic mice. Out of 88 genes screened there were 8 genes (red) that showed more
thn two-fold change in their expression pattern while one gene (blue) showed more than
two-fold reduction in its expression compared to GF control mice.
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The absence of any profound change in the expression of inflammatory cytokines
also supports this assumption. Modulation of MUC1 expression by BPC can also be
considered as an enhancement to the protective barrier function against enteric pathogens
such as Campylobacter jejuni and enteroaggregative Escherichia coli (EAEC), as MUC1
expression has been shown to limit the infection caused by these pathogens [139, 140].
This protective effect can be explained by two functional mechanisms of MUC1, one
MUC1 affects the thickness of the colon mucus in vivo and two, MUC1 helps to tether
the mucus layer to epithelial cell surface [141]. Thus, a well-thickened and attached
mucus layer efficiently protects the host from bacterial invasion by separating the
bacteria from coming in contact with epithelial cells.
There are two types of secreted MUCs – gel forming and non-gel-forming MUCs.
In the colon, MUC2 is the predominant secreted mucin and it belongs to gel forming
MUCs [142]. MUC2 mucin, constitutively produced by the goblet cells, forms the major
component of both inner firm and outer loose mucus layer in colon. The gut bacteria
occupy outer loose layer whereas the inner one, that is firmly adherent to the intestinal
mucosa, is devoid of bacteria [143, 144]. Thus, by forming the mucus layer, MUC2 play
a role in regulating gut homeostasis by keeping a minimal bacterial-epithelial cell contact
as well as immune tolerance to bacteria. More than that, it is a host defensive system
against pathogenic bacteria and its deficiency caused increased barrier disruption and
bacterial translocation [143, 145]. The over expression of MUC2 in our study indicates
that colonized bacteria might be able to enhance the mucus layer and thus improve the
gut barrier integrity. Increased expression of MUC2 may ensure the proper organization
of both inner and outer layer of mucus. Together with increased expression of MUC1, a
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thicker inner layer may form in gnotobiotic mice compared to germ free mice as the inner
firm layer was found to be slightly thinner in MUC1deficient mice [141]. Thus, in
gnotobiotic mice, the inner mucus layer will be more efficient in its protective role
especially against pathogenic bacteria. Additionally, increased MUC2 expression may
result in increased thickness of loose outer layer and thus allow the commensal bacteria a
better spatial organization and nutrient availability via glycan foraging. In other words,
colonization of BPC members can support the mucus degrading bacteria like
Akkermansia muciniphila that are known to responsible for several anti-inflammatory
properties in the gut. Apart from that, mucus induction by the presence of BPC members
also helps to reduce the defects in mucus associated with certain disease conditions and
attenuate the inflammatory conditions.
Fortification of antimicrobial peptide defense in the colon:
Colonization of BPC members also triggered the epithelial expression of
antibacterial compounds such as Reg3g and Reg3b (Figure 18). The recognition of the
bacteria or bacterial components by the innate immune system might be the reason for the
increased expression of these C-type lectins as it was explained by previous studies [146,
147]. Reg3g showed antibacterial activity against Gram-positive bacteria [146] while
Reg3b inhibits the bacterial translocation of Gram -negative bacteria [148]. Our
community of bacteria includes both Gram-negative and Gram-positive bacteria and its
colonization caused the expression of these antibacterial lectins. Triggering of the Reg3
proteins expression by the colonization of BPC members ensures the protection against
gram-positive pathogens, spatial segregation of other commensal bacteria as well as
maintenance of gut homeostasis. Lack of Reg3g cause aberrant mucus distribution as
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well as increased epithelial contact with microbiota [149]. However, the expression of
Reg3 proteins elicited by the members of the BPC was not drastic (< 5-fold) indicates
that either they are not strong elicitors of Reg3 proteins, or they might have been
sequestered by other innate defense mechanism like IgA as explained by Cash et al [146].
Being a simple community of three colonized members would be another reason for not
having a higher fold expression of Reg3g as seen in conventional or specific pathogen
free mice since intestinal Reg3g expression correlates with the microbial richness [150].
Resistin-like molecule β (RELMβ / Retnlb) is another bactericidal protein,
produced by intestinal epithelial cells and secreted to mucus. It also promotes the gut
homeostasis by limiting the contact between gut bacteria mainly Gram-negative bacteria
and the colonic epithelial surface [151]. Bacterial colonization has been found to be one
of the reasons for the enhanced expression of Retnlb [152] and the same could be the
reason for the enhanced expression (> 4-fold) of Retnlb in this study (Figure 18). One of
the reasons for increased expression of MUC2 in this study can be explained as the
outcome of enhanced expression of Retnlb [153].
Beta defensins are another set of antimicrobial peptides produced by the host
epithelial cells to ensure a healthy equilibrium at the mucosal surface. Beta defensins are
cationic peptides having antimicrobial activity against both Gram positive and Gram
negative bacteria [154]. Around 9 beta defensins were screened in this study for their
expression pattern at mRNA level between GF mice and BPC colonized mice. Out of 9,
beta defensin 37 (Defb37) showed more than two-fold change in expression in BPC
colonized mice (Figure 18). Analysis of the microbiota induced transcriptional responses
in intestinal epithelial cells have showed significantly increased expression of Defb37
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and Defb39 in conventionally reared mice compared to GF mice [155]. In case of Defb37
although not significantly different our result of more expression level is somewhat
corroborating with the previous study result. However, we did not get any expression
change in case of Defb39.
Presence of BPC influences expression of genes other than immunity:
BPC colonization and the resulted metabolic milieu in the colon caused more than
two-fold difference in the expression of Fatty Acid Binding Protein 2 (FABP2/I-FABP)
(Figure 18). FABP2 is a Free fatty acid (FFA) binding cytosolic protein and believed to
be involved in the uptake and intracellular trafficking of lipids in the intestine [156],
absence of which resulted in increased body weight gain and plasma triglycerides level in
mice[157]. High fat diet can cause upregulation of FABPs [158]. But in this study both
GF mice and the colonized mice received the same normal chow diet and thus ruled out
the possibility of diet being the reason for increased expression of FABP2 in the colon.
Thus, it is being assumed that the presence of gut bacteria could be another plausible
reason for this varied expression level between two groups of mice. This may indicate the
role of gut microbiota in the host lipid metabolism via FABP2. But then influence of
microbiota on the expression of FABP2 expression is a question. Microbial metabolism
or conjugation of fatty acids is a known phenomenon, for example several gut lactic acid
bacteria are capable of conjugating linoleic acid to conjugated linoleic acid (CLA) and a
ruminal bacterium Megasphaera elsdenii is one of them [159, 160]. The conjugated fatty
acid or poly unsaturated fatty acid (PUFA)-derived intermediate metabolites could be a
triggering factor for FABP2 expression. Since the microbiota is absent in GF mice, there
is no microbial conjugation of fatty acids and thus low expression of FABP2. The
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presence and colonization of Megasphaera indica in the BPC again supports this
plausible theory of microbial influence of FABP2.
G-protein coupled receptors (GPRs) such as Free fatty acid receptors 2 (FFAR2 or
GPR43), Free fatty acid receptors 3 (FFAR3 or GPR41) and Niacin receptor 1(GPR109a)
are receptors for short-chain fatty acids (acetate, propionate and butyrate). Since the
members of the BPC were able to produce butyrate in-vivo, it is important to see how it
affected the expression of SCFA receptors. The colonization of butyrate producers and
the accompanied SCFA production did not produce any significant change in the
expression of any of these GPRs. However, only one GPR that is FFAR2 or GPR43
showed more than two-fold change in the expression in the colon (Figure 18).
Since colonized members of the BPC were able to produce butyrate in the mouse
gut, and the butyrate is an energy source for the colonocytes, expression of a panel of
satiety related genes were analyzed. Out of 6 genes analyzed, insulin-like peptide 5
(Insl5) showed a down regulation of more than 2-fold. It is an orexigenic hormone
released from colonic L-cells, the elevated levels of which indicate energy deprivation
[161]. Based on previous reports Insl5 promotes glucagon-like peptide 1 (GLP-1)
secretion [162]. Analysis showed that GLP-1and peptide YY (PYY) produced by the
same L-cells did not show any difference in their expression by the colonization of BPC.
Role of SCFA in the gene expression profile:
More than the bacterial colonization, modulations of several host gene
expressions could be explained by the bacterial metabolites like SCFA. Compared to
germ free mice, BPC colonized mice had a significant amount of SCFA, including
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butyrate. Both in-vitro and in-vivo studies have shown that SCFA, especially butyrate,
are capable of inducing mucus production. SCFA can do this either through activation of
cholinergic nerves or via the induction of Prostaglandins from the subepithelial
myofibroblasts [45, 163-165]. Since GPR43 (FFAR2) is a G-protein coupled receptor
activated by major SCFA, the elevated expression of FFAR2 at the mRNA level might be
due to the presence of major SCFA in the BPC colonized mice colon. SCFA also might
have promoted the Reg3 proteins and beta defensins in a FFAR2 dependent manner as
explained by previous studies [47, 166].
It has been shown that depletion or absence of the gut microbiota cause reduced
SCFA levels and thereby increased expression of proglucagon (Gcg) in the colon and
basal level of incretin hormone GLP-1 in plasma. Increased GLP-1 is proposed to
stimulate insulin secretion, which is reported to be an adaptive response to energy
deprivation in the colon [167]. Thus, the absence of significant change in the expression
of Gcg in the colon by the colonization of BPC indicates that production of SCFA
especially butyrate by BPC able to achieve energy homeostasis in the colonized mice.
This is further supported by the finding that BPC colonization resulted in more than twofold reduction in the expression of Insl5 in the colon (Figure 18). Insl5 is considered as
an energy sensor in the colon[168]. The absence of SCFA, especially butyrate, cause an
energy depleted condition of colonocytes in the GF mice resulted in increased colonic
expression of Insl5. Restoration of SCFA levels especially butyrate in the colon by
functional gut microbiota resulted in reduced expression of Insl5 similar to refeeding
calorie-restricted mice [168-170]. In conclusion, what we can say is that changes in the
gene expression profile observed in this study may not be merely due to the colonization
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or direct interaction of bacteria with the host alone, but it could be due to the metabolites
produced by the microbial activities.
Modulation of the adaptive immune system achieved by the colonization of BPC in the
mouse gut
To understand further about the immune tolerance achieved by the host with the
colonization of BPC members, profiling of host’s adaptive immune phenotype was
performed using the total lymphocytes (CD45+) from both secondary lymphoid organ
and peripheral blood. Using flow cytometry techniques, major adaptive immune cell
populations such as B-cells (CD19+), ∞βT cells, γδT cells were analyzed. Within ∞βT
cells, subsets of T-helper (CD4+), T-cytotoxic (CD8+), Th17 (RORγ+), and Treg
(Foxp3+) were analyzed. Marked differences in the adaptive immune phenotypes were
observed between GF and colonized mice at the systemic levels (Figure 19,and Figure
20). Similarities and differences were visible in a particular cell population if we compare
between two different tissues. For example, analysis shows that percentage of B cells in
the total lymphocytes was significantly lower in the spleen of BPC colonized mice while
it was significantly higher in the peripheral blood. Decreased B cells in the blood of GF
mice matched with previous reports [171]. Previous studies have shown little effect of
microbiota on the splenic B cells, whereas this study colonization of BPC members
resulted in a reduced percentage of B cell (CD19+) population in the spleen (Figure 19).
A similar phenotypic profile was found in case of ∞βT cells both in spleen and
PBMC, where percentage of ∞βT cells was significantly decreased in BPC colonized
mice compared to GF mice. This was opposite to the previously reported scenarios where
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a decrease of ∞βT cells was found in GF mice [171]. Although there was a significant
increase in the CD4+ T cells in the spleen, the percentage of Th17 cells were found to be
significantly reduced in colonized mice. The reduction of Th17 cells was also visible in
the PBMC of the colonized mice but without any significance. Together these findings
indicate that BPC colonization results in host immune homeostasis by not responding
overly to the colonized bacteria, instead regulating the inflammatory response by
reducing the Th17 cell population. This assumption is again supported by the absence of
any significant difference in the gene expression of Th17 cytokine in the colon tissue.
A minor part of the T cell population (1-5%) in the peripheral blood and spleen is
represented by the γδT cells. These cells are developed in the thymus and become part of
the intra epithelial lymphocytes as epithelial γδT cells [172]. Compared to GF mice, we
did not get any significant difference in the level of γδT cells in spleens of the BPC
group. However, there was a significant difference in the level of γδT cells in the
peripheral blood. An increase of γδT cells in the blood ensures immune responses against
viruses, intra cellular bacteria and malignancies at the largest epithelial tissues in the
body, i.e., the epidermis and intestine [172, 173].
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Figure 19. Effect of colonization of selected members of human gut bacteria on the
immune cell population of secondary lymphoid organ (Spleen) of the mice. Boxplots
represents the percentage of different population of lymphocytes in the spleen of both
colonized as well as GF mice. Statistical analyses were performed using Welch’s test
using GraphPad prism v 9.0.
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Figure 20. Effect of colonization of selected members of human gut bacteria on the
immune cell population of peripheral blood of the mice. Boxplots represents the
percentage of different population of lymphocytes in the PBMC of both colonized as well
as GF mice. Statistical analyses were performed using Welch’s test using GraphPad
prism v 9.0.
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3.4

Conclusion

…………………………………………………………
In conclusion, this study identifies human gut bacteria that are capable of modulating
the host immune system contributing to the maintenance of gut homeostasis. By
successfully and stably engrafting in the mouse gut, this study once more establishes
mouse gut system as a perfect model of studying the microbial assemblage and the hostmicrobe interaction of selected subset of members of human gut bacteria. Failure of
colonization of one of the members highlight the use of BPC and the gnotobiotic mouse
models for the further exploration of ecological interactions that can exist between
members of the gut bacteria. Furthermore, the consortium developed in this study (BPC)
represents a double-edged sword in the context of bacterial therapeutics as the colonized
members of the BPC can act as a stand-alone source of major SCFA, especially butyrate
under a normal dietary condition. Apart from that, the simple consortium developed in
this study also can be a cornerstone of future development of microbial consortium using
a top up approach focusing towards bacteriotherapeutic or next generation probiotics.
Overall, this study contributes towards the effort of identifying the effector gut microbes
and understanding the role of human gut microbial entity otherwise considered as
‘another organ’ in the body.
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CHAPTER 3. PROTECTIVE EFFECT OF BUTYRATE PRODUCING
CONSORTIUM AGAINST DSS INDUCED COLITIS
4.1 Introduction
……………………………………………………………………………

Inflammatory bowel disease (IBD) is a general term that represents a group chronic
relapsing and remitting inflammatory conditions of the GIT that is ulcerative colitis (UC)
and Crohn’s disease (CD). The etiology of IBD is multifactorial that includes diet,
lifestyle, genetics, immune system, gut microbiota dysbiosis and environmental factors.
[81]. The incidence of this disease in the last two decades increased over the past few
decades and prevalent in both developed and developing countries [174].
Pharmacological approaches using traditional medicines are not much effective as those
are aiming to control the diseases symptoms rather reducing its relapse [81]. Microbial
dysbiosis in gut is characteristic of IBD featured by loss of SCFA producing commensal
bacteria and blooming of facultative anaerobic invasive pathogen like E. coli [16, 67,
174]. Modulation of the gut microbiota to restore the state of eubiosis have been
suggested as the treatment strategy to treat immune mediated disease such as IBD [81].
Results from both in vitro and in vivo studies using butyrate-producing bacteria as
bacteriotherapeutic have validated this bacteriotherapeutic intervention as a promising
treatment modality effective in curing IBD [16, 24, 74].
In this study, the hypothesis, that colonization by a consortium of four butyrateproducing bacteria (BPC) would attenuate the inflammatory responses, was tested using
chemically induced colitis models in mice. Since the DSS induced colitis in mice is one
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of the best models of human IBD conditions, this study explore the therapeutic potential
of the BPC.
4.2 Material and Methods
…………………………………………………....................................
4.2.1

Bacterial strain abundance mapping
To assess the association of selected four butyrate producers in IBD conditions,

an abundance mapping at the strain level was performed using publicly available 1338
gut metagenome sequencing data sets collected from the US individuals as a part of a
longitudinal cohort research study by Lloyd et al [175]. Mapping was performed with
similar procedure that described in chapter 1. Briefly, annotated protein files of individual
bacterial strains were mapped against metagenomic sequence reads after cleaned for host
reads using Kaiju bioinformatics platform. The percentage abundance of each bacterial
strain was then summarized and plotted as scattered dot plot.
4.2.2

Mice experiment

Six-week-old germ-free mice (C57BL/6) maintained in our mice breeding facility
were used for the experiment as per the protocol (2003-020A) approved by South Dakota
State University (SDSU) animal studies committee and under the regulations of
Institutional Animal Care and Use Committee (IACUC), SDSU. All animals were
maintained at normal chow diet and adlibitum water under 12-hour light and dark cycle.
Three groups of mice were used for the study. Two groups of mice were colonized with
BPC and one group was kept as GF control group. Colitis was induced in this GF control
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group and one gnotobiotic group using DSS and the remaining one group of gnotobiotic
mice was used as negative control without colitis (Figure 21).

Figure 21. Experiment outline for DSS induced colitis experiment.

4.2.3

DSS induction of colitis in mice
Colitis was chemically induced in mice as per the protocol mentioned by Wirtz et

al [176] with some modifications. Dextran sulfate sodium salt (MP Biomedicals, 30-50
KDa) was used at a level of 1.5% in autoclaved drinking water. Mice were fed with DSS
containing water ad libitum for 6 days after which they were euthanized by cervical
dislocation and collected samples for further analysis. All animals started showing rectal
bleeding on 5th day onwards and one animal died in the GF mice treated with DSS on 6th
day of treatment. However, onset of colitis was verified using fecal occult test performed
on 3rd day.
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4.2.4

Fecal occult blood test

The onset of colitis induction was verified by occult blood test using fecal sample.
Whatman filter paper coated with a thin film of guaiac was used for the test. After
applying feces on one side of the guaiac pretreated whatman filter paper, one or two
drops of 3% hydrogen peroxide was then dripped on the other side. Test was considered
positive for blood when there was a rapid blue color change on the Whatman paper.
4.2.5

Colon tissue gene expression profiling using qRT-PCR
A panel twenty-two genes, that include inflammatory markers, pro and anti-

inflammatory cytokines, TLRs, AMPs, were used to assess the status and the mechanism
by which BPC influence the colitis condition. The list of primers used in this study were
given in table. Mouse beta actin (Actb ) and Glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) genes were used as housekeeping genes for normalization. All the procedures
including RNA extraction from colon tissue, cDNA synthesis and qRT-PCR were
performed as per the methods described in chapter 2. Delta CT was calculated for each
gene and for each animal using the geometric mean of Housekeeping gene CT. All the
four groups – untreated GF control and BPC colonized gnotobiotic mice along with their
DSS counterparts were compared for the mRNA expression levels for the above
mentioned all 22 genes. Statistical analysis and generation of figures were performed in
GraphPad Prism v 9.0.
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Table 9. Details of mouse qRT-PCR primers used in this study.
Symbol

Description
Myeloperoxidas
e

Forward Primer (5`-3`)

Reverse Primer (5`-3`)

AGTTGTGCTGAGCTGTATGGA

CGGCTGCTTGAAGTAAAACAGG

GTCTAGTGGCAACTCTACAGACC

AGCTCCAAGGTTCCTTCTTCT

CTTCTTCTTGTTGAGCTGGACTC

CTGTGGAGGTCACTGTAGACT

Il1b

Lipocalin 4
Matrix
metallopeptidase
13
Interleukin 1
beta

GAAATGCCACCTTTTGACAGTG

TGGATGCTCTCATCAGGACAG

Il4

Interleukin 4

GGTCTCAACCCCCAGCTAGT

GCCGATGATCTCTCTCAAGTGAT

Il6

Interleukin 6

TAGTCCTTCCTACCCCAATTTCC

TTGGTCCTTAGCCACTCCTTC

Il10

Interleukin 10

GCTCTTACTGACTGGCATGAG

CGCAGCTCTAGGAGCATGTG

Il17a

Interleukin 17A
Tumor necrosis
factor
Interferon
gamma
Transforming
growth factor,
beta 1
Nuclear factor of
kappa light
polypeptide gene
enhancer in Bcells 1, p105
Toll-like
receptor 2
Toll-like
receptor 4

TTTAACTCCCTTGGCGCAAAA

CTTTCCCTCCGCATTGACAC

CCCTCACACTCAGATCATCTTCT

GCTACGACGTGGGCTACAG

ATGAACGCTACACACTGCATC

CCATCCTTTTGCCAGTTCCTC

CTCCCGTGGCTTCTAGTGC

GCCTTAGTTTGGACAGGATCTG

ATGGCAGACGATGATCCCTAC

TGTTGACAGTGGTATTTCTGGTG

GCAAACGCTGTTCTGCTCAG

AGGCGTCTCCCTCTATTGTATT

ATGGCATGGCTTACACCACC

GAGGCCAATTTTGTCTCCACA

Forkhead box P3
RAR-related
orphan receptor
gamma
Regenerating
islet-derived 3
gamma

ACCATTGGTTTACTCGCATGT

TCCACTCGCACAAAGCACTT

GACCCACACCTCACAAATTGA

AGTAGGCCACATTACACTGCT

ATGCTTCCCCGTATAACCATCA

GGCCATATCTGCATCATACCAG

Mucin 2
Regenerating
islet-derived 3
beta
nitric oxide
synthase 2,
inducible (Nos2)

ATGCCCACCTCCTCAAAGAC

GTAGTTTCCGTTGGAACAGTGAA

ACTCCCTGAAGAATATACCCTCC

CGCTATTGAGCACAGATACGAG

GTTCTCAGCCCAACAATACAAGA

GTGGACGGGTCGATGTCAC

Actin, beta
Glyceraldehyde3-phosphate
dehydrogenase

GGCTGTATTCCCCTCCATCG

CCAGTTGGTAACAATGCCATGT

AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA

Mpo
Lcn4

Mmp13

Tnf
Ifng

Tgfb1

Nfkb1
Tlr2
Tlr4
Foxp3

Rorc

Reg3g
Muc2

Reg3b

iNOS
Actb

Gapdh

83

4.3

Results and Discussion

.…………………………………………………………………………
4.3.1

Association of selected butyrate producers in healthy and IBD conditions
Dysbiosis and associated depletion or enrichment of species in metagenomic

samples of individuals with IBD compared to non IBD control individuals have been
reported in several previous studies [121, 174, 175, 177]. Depletion of anaerobic species
such as Faecalibacterium prausnitzii and Roseburia hominis has been reported as a
notable feature in IBD individuals [16, 175]. At the same time, IBD metagenomes were
found enriched with Ruminococcus torques and Ruminococcus gnavus and facultative
anaerobes such as E. coli [175, 177]. Although the causal relationship of these enriched
microbial species was not clear, because of the increased relative abundance of these
species corresponded to increased disease activity in IBD, it has been considered to avoid
such microbial features from any microbiota-based therapeutics. On the other hand,
enrichment of depleted species has been found to be promising in restoring the dysbiosis
as well as attenuating the inflammation associated with IBD[16, 17]. Thus, to know the
association of selected species in this study, the abundance of those were assessed in
publicly available stool metagenomes collected from both IBD and non-IBD individuals
as a part of longitudinal cohort study [175].
We checked the abundance of all 4 species in 598 metagenomes from 50 CD
subjects and 375 metagenomes from 30 UC subjects and compared against the abundance
in 365 metagenomes from 27 non-IBD subjects (Figure 22). Interestingly a differential
abundance of all four bacteria was found in at least one of the IBD conditions. A
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significant low abundance was found in both CD and UC in case of Agathobaculum
butyriciproducens (Ruminococcaceae) and Megasphaera indica (Veillonellaceae). A
significant reduction was noticed in case of Coprococcus comes (Lachnospiraceae) but
only in CD and not in UC. Only one that showed a significant abundance in IBD
metagenome datasets compared to that of non-IBD was the Butyricimonas paravirosa
(Odoribacteraceae). However, the increase was found only in CD conditions and that too
for a difference of 0.45 % between the median of CD and non-IBD controls. While there
was no significant difference between UC and non-IBD control metagenome datasets
(Figure 22). The increased abundance of this species in CD could be related to the disease
occurrence or it could be because of change in the metabolic milieu and/ or gut microbial
composition, but to verify the exact factor that caused this increase in the abundance
further investigations are needed.
The onset of IBD is associated with depletion of microbial members mainly from
the phyla Firmicutes and Bacteroidetes and notably the butyrate producers. A hypothesis
was formulated that the colonization of the selected four bacteria have some role in
preventing or attenuating the inflammatory damage caused by colitis in the gut as the
selected four bacteria are butyrate producers from these two phyla.
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Figure 22. Abundance of BPC members in the IBD and non-IBD gut metagenomic
datasets from Lloyd et al study [175]. Scatter dot plot shows all four bacteria except one
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showed significant decrease in their abundance in atleast one IBD conditions compared to
non-IBD controls. Butyricimonas paravirosa (Odoribacteraceae) was significantly
abundant in CD but not in UC (A). Agathobaculum butyriciproducens
(Ruminococcaceae) and Megasphaera indica (Veillonellaceae) were found significantly
less abundant in both CD and UC. Coprococcus comes (Lachnospiraceae) was found
significantly less in CD compared to non-IBD control datasets but not in case of UC. The
black line indicates mean with standard error of mean (SEM). Asterisk (* ) indicates level
of significance where * means p ≤ 0.05 , ** means p ≤ 0.005

, **** means p <

0.0005).

4.3.2

Prophylactic role of BPC against DSS induced colitis
To test the hypothesis, DSS (dextran sodium sulfate) induce colitis in GF and

gnotobiotic mice colonized with BPC were used. Colitis induced by DSS in mice is a
good model that mimic human IBD condition. To understand the prophylactic role of
BPC, one group of GF mice colonized with BPC for 14 days prior to the induction of
colitis were used. GF mice with colitis were used as colitis control group. All the mice
were given 1.5% of DSS in drinking water for six days after which they were euthanized,
and samples were collected for further analysis. A GF group and gnotobiotic group mice
that were fed with normal drinking water were taken as negative controls for colitis.
4.3.2.1 Microbial community structure and composition before and after the
induction of colitis
Six-week-old GF mice were colonized with BPC by oral gavaging. A total of two
oral gavaging (one per day) was given and allowed to colonize for 14 days, after which
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they were split in to two groups. One group was then treated with 1.5% DSS for 6 days in
drinking water while another group received normal drinking water. On the seventh day,
mice were euthanized to collect the intestinal content and the bacterial community
structure was assessed using 16S rRNA gene sequencing. Fecal samples collected on day
13 were used to profile the community before DSS treatment.
All four members of the consortium were found colonized in the gut before and
after the DSS treatment ( Figure 23). A highest abundance was showed by Coprococcus
comes (Lachnospiraceae) and the community structure was found stable even in the
inflammatory condition induced by the DSS treatment.

Figure 23. Community structure formed by the BPC members before and after DSS
treatment. 16S rRNA gene sequencing-based community profiling shows the colonization
of all members of BPC.
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4.3.2.2 Health assessment of the colon when induced colitis after colonized with
BPC.
Induction of colitis was achieved in all DSS treated mice after 3 days as
confirmed by the fecal occult blood test and by visible rectal bleeding on 5th day after
treatment. Although all the mice showed a similar clinical symptom, mice started to die
on 6th day of treatment in GF colitis group indicating that the survival rate of BPC treated
mice was higher compared to that of GF colitis mice (Figure 24).
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Figure 24. Survival plot showing the survival rate of different groups of mice with and
without DSS treatment.

Upon gross observation, visible changes were noticed between the colon of GF
and gnotobiotic (BPC treated) mice (Figure 25). Black colored more watery contents
were present in GF group with colitis compared to gnotobiotic counterpart. Difference
was also noticeable in the size of cecum where GF mice had a bigger cecum compared to
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gnotobiotic group. The cecum of the gnotobiotic mice were less black in color and the
contents appeared as pasty solid in consistency. The length of the colon also showed
visible difference where gnotobiotic mice were presented with longer colon that the GF
mice.

Figure 25. Representative figure showing the gross difference of the colon between GF
and BPC treated mice under colitis.

Evaluation of H&E stained cross sections of colon tissue showed critical damage
in the mucosal architecture of GF mice with colitis (Figure 26). Loss of villi morphology
with villus atrophy, loss of basal crypts and goblet cells along with areas of epithelial
erosions were clearly present in GF mice with colitis. Marked neutrophil infiltration with
submucosal edema were also present in these mice. However, in BPC colonized mice
although there was moderate neutrophil infiltration, the mucosal architecture was mostly
intact without any loss of villi, crypts and goblet cells but with mild villus atrophy. Intact
epithelial layer without any disruption was also present in gnotobiotic mice indicating
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that colonization of BC has some protective effect against the development of DSS
induced colitis by upholding the colon mucosal architecture and the integrity.

Figure 26 .Histopathological comparison of colon tissue after induction of colitis with
DSS. Photographs showing the colon tissue cross sections after H&E staining. A) Germ
free mice B) Gnotobiotic mice colonized with BPC

4.3.2.3 Gene expression profile of colon tissue
To understand the effect of BPC bacteria on colitis condition, expression of a
panel of 20 genes were performed in colon tissue. A comparison of all groups of mice,
which include GF mice treated with either DSS or BPC or BPC followed by DSS and GF
mice group without any treatment were performed. Out of 20 genes were analyzed, a
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significant difference in the expression was not found in case of 12 genes while 8 genes
showed a significant difference in at least one comparison between two groups (Figure
27).
Expression profile of inflammatory markers such as myeloperoxidase (MPO),
Lipocalin (LCN4), Matrix metalloproteinases (Mmp13) and iNOS were analyzed to see
the progression of inflammation between different groups of mice. MPO activity is a
measure of neutrophil infiltration in colon and inflammatory tissue shows marked
upregulation of MPO. Inflammatory bowel disease is also characterized by increased
production of iNOS. Reduced expression of iNOS is an indication of amelioration of
inflammation [178]. However, both markers were not showing any difference in their
expression in colon (Figure 27). It was Mmp13 that showed a significant difference in the
expression between groups. It was significantly overexpressed in colon tissue of GF mice
with colitis compared to gnotobiotic mice colonized with BPC and untreated GF mice.
However, any significant difference was not detected between gnotobiotic mice colitis
and GF colitis mice may be because of the increased SD (Figure 27). Matrix
metalloproteinases are mediators of inflammatory responses. A higher expression of
MMP13 mRNA was reported in biopsy samples from IBD patients. MMP13 cause
shedding of TNF and its elevated levels which in turn results in inflammation of the gut
along with depletion of mucus and disruption of barrier integrity due to aberrant tight
junction protein functions and ultimately increased intestinal permeability [179].
Significant increase in the expression of colon tissue TNF in GF mice with colitis
compared to untreated GF control group indicates a more pronounced inflammatory
response in the DSS treated GF mice group.
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Figure 27. Expression profile of various inflammatory genes in the colon tissue analyzed
by qRT-PCR. Barplots showing gene expression as measure of dCT normalized using the
expression of housekeeping genes mouse beta actin and GAPDH. A significantly higher
expression of IL4, FOXP3 and Reg3b were found in gnotobiotic mice with colitis
compared to GF untreated group but not with GF colitis group.

IBD is characterized by Th1 mediated immune response with increased levels of
IFNg, and TNF as in case of CD [180] and a Th2 response with increased IL6 or reduced
IL10 in case of UC [180]. But all these cytokines were showed any significant difference
in their expression between treatment groups except in case of TNF which showed a
significant difference in DSS treated GF mice compared to untreated GF mice. Both IL17
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and anti-inflammatory cytokine TGFb were also not showed any significant difference in
their expression in the colon tissue.
In mice, FOXP3 is the best marker for regulatory T cells [181]. An increased
expression of FOXP3 was found in the colon tissue of gnotobiotic mice colonized with
BPC compared to untreated GF mice control group. There was no significant difference
between GF colitis and gnotobiotic colitis group. However, the difference in expression
was found closely significant between gnotobiotic colitis group and GF untreated group.
Increased expression of this transcription factor in the BPC colonized mice compared to
untreated GF mice is an indication that colonization of BPC bacteria has some influence
in the differentiation of Treg cells and thereby the role host’s gut immune homeostasis.
An interesting observation found in this study was the difference in the expression
of antimicrobial peptide Reg3b. Compared to untreated GF mice group all other treated
groups showed an increase in the expression of this defense system in the colon. Studies
using transgenic mice that are deficient of Reg3b (Reg3b−/−) showed its protective role
in attenuating the DSS induced colitis in mice [182]. Mice exposed to both bacteria and
DSS showed more expression of Reg3b in the colon tissue indicating that disruption of
colon barrier integrity by the colitis and associated translocation of commensal BPC
bacteria might be the reason for it.
It was difficult to draw any conclusive reasons for this protective effect from the
gene expression profile we tested as there was no significant difference between the GF
and the BPC colonized mice under colitis condition. Because of the same reason
especially in case of inflammatory genes, it is evident that the presence of these bacteria
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not causing any deterioration of the colitis. This is further supported by the absence of
any significant increase in the expression of markers for inflammation. In order to
understand the exact mechanisms by which these bacteria elicit their protective effect,
expression pattern of more genes, for example TJ proteins for barrier integrity, needs to
be performed.
4.3.2.4 Modulation of immune cell profile by BPC in colitis condition

To find out any cellular level response elicited by the BPC in colitis, profiling of
immune cell populations from BMC and spleen were performed in similar approach that
we used in chapter 2. There were no a significant change in the cell profiles in DSS
treated animals except in case of TCRb cells. A significant reduction of TCRb cell
population was found in both spleen and PBMC of gnotobiotic mice with colitis
compared to its GF counterpart (Figure 28 and Figure 29). This was similar to the result
obtained in case of gnotobiotic mice without colitis in the previous experiment (Figure 19
and Figure 20).
There were differences in the immune profiles between GF and gnotobiotic group
as compared to previous experiment (Chapter 1) without DSS. However, since there were
no significant differences between GF and gnotobiotic group those changes are
inconclusive. Although not significant, an increase in Th17 cell number was noticed in
the spleen of gnotobiotic mice under colitis but not in PBMC. The assumption is that the
reason for this change in profile could be recognition of molecular patterns associated
with gram -positive and negative members of the BPC.
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Figure 28. Profile of immune cell populations in spleen under colitis condition. Box plots
shows the percentage of respective cell populations as a percentage of parent cell
population (Y axis). Graphs represents the comparison of each cell population between
Gf and gnotobiotic mice with colitis. Statistical analyses were performed using Welch’s
test using GraphPad prism v 9.0.
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Figure 29. Profile of immune cell populations in PBMC under colitis condition. Box plots
shows the percentage of respective cell populations as a percentage of parent cell
population (Y axis). Graphs represents the comparison of each cell population between
GF and gnotobiotic mice with colitis. Statistical analyses were performed using Welch’s
test using GraphPad prism v 9.0.
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4.3.2.1 DSS effect on SCFA profile
Gas chromatographic analysis of cecal contents showed a significant difference in the
major SCFA between colitis induced GF and gnotobiotic mice group (Figure 30).
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Figure 30. SCFA profile of cecal contents from GF and gnotobiotic mice with colitis.
Statistical analyzes were performed using Welch’s t test in GraphPad prism v 9.0.

No detectable levels of measured SCFA were found in GF mice cecal content
except for acetic acid. However, the level of acetic acid was not significantly different
between colitis induced GF and gnotobiotic groups. But significantly higher levels of
other major SCFA in gnotobiotic mice indicate that the colonized bacteria were able to
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produce these acids even in the chemically induced colitis condition under normal chow
diet.
Since the immunological responses elicited in the gnotobiotic group with colitis
were not significantly different from GF mice colitis, the level of butyrate was compared
between gnotobiotic mice with and without colitis to see whether introduction of DSS
and associated change in the gut environment have any effect on the cecal butyrate level.
Interestingly, a significant reduction in the level of butyrate was detected in DSS treated
gnotobiotic mice cecal contents (Figure 31). Since butyrate is the major energy substrate
for colonocytes and more than 95% of the SCFA are taken up the colonocytes, the
assumption is that the level of butyrate may not even sufficient to meet the energy
requirements of colonocytes which are in a state of high stress produced by the colitis
condition. Thus, the negligible effect of butyrate and the responses elicited by the
bacterial colonization might have been the reason for any profound inflammation
attenuating changes at the cellular and molecular level. However further verification is
needed to draw this conclusion.
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Figure 31. Butyrate level in the cecal content of BPC colonized mice with and without
DSS induced colitis. Bar plot represents the butyrate level in micromolar concentration
detected in the cecal content of gnotobiotic mice with and without DSS treatment.

4.4 Conclusion
……………………………………………………………………………
In conclusion, based on the histopathological evidence and gross morphology the
colonization of BPC members has some protective effect at least by maintaining the
structural morphology and integrity of the colon. Absence of any significant difference in
the expression of proinflammatory responses in BPC treated mice compared to GF mice
under colitis indicate that the presence of these bacteria does not cause any aggravation in
the inflammatory condition. Since the anti-inflammatory responses and the immune cell
profiles are also not significantly different, the assumption is that these bacteria protect
and maintain host gut health in inflammatory condition by some other mechanisms such
as modulating tight junction protein assembly and enhancing the barrier integrity.
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SUMMARY

The overall goal of this study was to explore the functional properties of human gut
bacteria whose beneficial effects are yet unknown. To do so we integrated multiple
selection criteria in our approach by which we selected four bacteria that are
metabolically efficient to produce butyrate and competitively fit to colonize when in
complex microbiota. We elucidated their immune modulatory functions being in a
community as the properties elicited when mono-colonized may not be reflected when
the strain is in a community. In order to do that we designed the consortium in such a
way that it will accommodate members of major gut bacterial phyla, that is Firmicutes
and Bacteroidetes, and both gram negative and positive fractions. Thus, the methodology
we applied here represents an effective way of screening the properties of gut bacteria
using in-vivo model.
Here we could successfully engraft a consortium of butyrate producers (BPC) in
germ free mice colon to study their beneficial properties. The members of BPC were
efficient to form a community and enough to produce butyrate under normal diet
condition. They were efficient in maintaining gut homeostasis without any excessive
inflammatory reactions but in enhancing the innate immune defense of the host and
development of colon. Without any dietary intervention, they stably persisted in an
inflammatory condition and contributed to the betterment of gut health in DSS induced
colitis. Based on the performance under normal condition, we believe that these bacteria
will be much more efficient in protecting the gut when integrated with dietary
interventions such as fiber supplement. Thus, these bacteria might be potential
therapeutic strains for disease like IBD. More than that, their consistent presence in both

103
healthy and disease conditions with reduced abundance in disease condition make these
bacteria as candidates for donor microbiota screening for FMT. Enhancement of innate
defensive system of the host also indicates that the presence of these bacteria might be
efficient in evading pathogen colonization. Above all, the consortium we developed in
this study form a baseline community which allows generation of better consortia by a
top up approach using other butyrate producers from the human gut.
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